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ABSTRACT 
   
DNA nanotechnology has been a rapidly growing research field in the 
recent decades, and there have been extensive efforts to construct various types of 
highly programmable and robust DNA nanostructures. Due to the advantage that 
DNA nanostructure can be used to organize biochemical molecules with precisely 
controlled spatial resolution, herein we used DNA nanostructure as a scaffold for 
biological applications. Targeted cell-cell interaction was reconstituted through a 
DNA scaffolded multivalent bispecific aptamer, which may lead to promising 
potentials in tumor therapeutics. In addition a synthetic vaccine was constructed 
using DNA nanostructure as a platform to assemble both model antigen and 
immunoadjuvant together, and strong antibody response was demonstrated in 
vivo, highlighting the potential of DNA nanostructures to serve as a new platform 
for vaccine construction, and therefore a DNA scaffolded hapten vaccine is 
further constructed and tested for its antibody response. Taken together, my 
research demonstrated the potential of DNA nanostructure to serve as a general 
platform for immunological applications. 
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CHAPTER 1 INTRODUCTION 
1.1 Introduction of DNA nanotechnology 
DNA, in Nature, is the genetic material that encodes all the information to 
direct the development and function of all living organisms. In DNA 
nanotechnology, DNA molecules are used mainly as a structural material to build 
nanometer scale architectures and devices.   
Dr. Nadrian Seeman proposed the concept of DNA nanotechnology thirty 
years ago1. He first described the idea of using DNA to build three-dimensional 
lattices to place the target molecules such as protein1, as shown in Figure 1.1. The 
rationale behind this idea was because single-stranded DNA forms hydrogen 
bonds to its complementary strand to form a DNA duplex following the simple, 
but precise, Watson-Crick base paring (adenine pairing with thymine and cytosine 
to guanine) He proposed that it is possible to rationally design DNA strands with 
certain sequences, that would allow each strand to fit in the proper orientation to 
achieve a target structures. 
244 N. C. SEEMAN 
FIG. 5. N-connected networks. Four different N-connected networks are shown in stereo- . . . These are all indicated as forming cubic lattices, although thjs is certainly 
“,‘,3p~e~~~~~$o&c dark lines represent double helical stretches of nucleic acid. The large 
circles represent junction regions of the appropriate rank. The short lines on the periphery 
of each figure represent unsatisfied valences. From the top, 
these are respectively units of 3, 
4, 5 and fj connected three-dimensional networks. 
 
Figure 1.1 A representative connected network proposed by Nadrian Seeman. 
The lines indicate the double helical stretches of DNA.1 
 
The Holliday junction is a naturally existing phenomenon during DNA 
recombination2 and is one of the first DNA building blocks (named as “DNA tile” 
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to illustrate the concept of using DNA as a building material) studied. During 
DNA recombination, the Holliday junction has to be mobile enough to allow  
branch migration and subsequent recombination, due to the fact that there is 
sequence symmetry 3. However, to build some DNA nanostructures, the crossover 
points have to be designed as more rigid, therefore limiting mobility, which could 
then significantly stabilize the formation of the structure. This became achievable 
by carefully designing the DNA sequences at the branch point.3 
After immobilization of the Holliday junction, researchers have since 
constructed various DNA nanostructures from one- to two- and to three-
dimensional4-9. Among all the DNA nanostructures, they are mostly constructed 
from basic DNA tiles, such as double crossovers (DX),4 triple crossovers (TX),10 
paranemic crossovers (PX),5 multi-arm DNA,11 4x4 DNA tile,12 and DNA 
origami assembled by using a circular M13 phage genomic DNA as a scaffold to 
facilitate the construction of DNA nanostructures.6 The self-assembly of DNA is 
autonomous and programmable, and this unique feature makes it possible to 
utilize computer to design and simulate its structure and geometry. Nowadays, 
there are several software or online tools specially programmed to design 
different types of DNA nanostructures [Tiamat,13 NanoEngineer (Nanorex, Inc.), 
CaDNAno14] and to predict the geometry of DNA nanostructures (CanDo15, 
Nupack16), rendering it more and more convenient to construct DNA 
nanostructures that may fit into different applications. The pool of all the 
constructed DNA nanostructures provides a broad spectrum of nano-devices to 
  3 
explore their applications in fields such as DNA computing, energy transfer, and 
nanomedicine. 
 
 
Figure 1.2 Representative DNA nanostructures.  a) Two dimensional DNA arrays 
and origami. Left12, center17, right6 b) Three-dimensional nanostructures 
  4 
constructed by DNA framework. Top left18, top center19, top right20,21; c) Three-
dimensional DNA origami, left22, center9. right8. 
 
1.2 Nanomedicine Applications of Functionalized DNA Nanostructures  
One big challenge in nanotechnology is to precisely control and manipulate 
materials at the nanometer level. Using DNA as the building material has 
demonstrated the potential to meet this challenge, because of the simple and 
predictable Watson-Crick base-pairing principle. By carefully designing the 
sequences, researchers are able to control the configuration and conformation of 
DNA architectures and to position various molecules or nanoparticles onto the 
nanostructure in site-specifically.23-28 The controllability and versatility makes it 
an ideal platform to carry out multiple functions, for example in nanomedicine. 
The European Science Foundation has defined nanomedicine as “the science 
and technology of diagnosing, treating and preventing disease and traumatic 
injury, of relieving pain, and of preserving and improving human health, using 
molecular tools and molecular knowledge of the human body”29. In this book 
chapter we review the nanomedical applications of utilizing functionalized DNA 
nanostructure for disease diagnosis, disease treatment, and disease prevention. as 
well as the safety and potential of these structures for clinical applications. 
 1.2.1 Functionalized DNA nanostructures for diagnosing disease 
DNA nanostructures possess the unique feature of high programmability 
and addressability, and these features allow for spatially specific presentation of 
different types of recognition molecules on the scaffolds for manipulation of 
various DNA modules at the nanometer level23-28. Moreover, various signal-
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triggered switchable DNA nanostructures have been constructed30, which, in 
combination with functionalized DNA nanostructures render it possible to 
construct many detection devices for diagnosis.   
With the development of various chemical conjugation techniques, 
nowadays it is practically convenient and technically feasible to link multiple 
recognition molecules, such as proteins or peptides like receptors and their ligand, 
antibodies and antigens, or nucleic acids like aptamers and anti-sense RNA), and 
quantum dots (QD) and fluorophores, to the DNA strand either covalently through 
chemical linkers or non-covalently through DNA hybridization or recognition 
interactions. These modified DNA oligonucleotides could then be incorporated to 
the DNA scaffolds, either constructing a target-recognizing module or by building 
a signal-transducing module for detection. 
One development that employs DNA nanostructure for target detection 
has been achieved by the incorporation of aptamers onto the DNA nanostructure. 
As summarized in a well-written review by Tan31,32, aptamers, which are single-
stranded DNA or RNA that have been selected in vitro to bind to a broad variety 
of target molecules, possess unique features such as strong and specific binding, 
robust synthesis and chemical modification,31 and the capacity of carrying a host 
of biological functions such as regulation of protein function, or serving as a 
ligand agonist 33,34 or antagonist.35 With the help from the rapidly developing field  
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of aptamers, the role of these DNA designs in nanomedicine, especially in disease 
diagnosis, was advanced in a significant way.  
One example is the incorporation of different types of aptamers to the 
DNA origami, rendering it a multi-functional detection platform for protein 
molecules.36 With the development of a larger aptamer database37 and DNA-
protein conjugation techniques, it is now possible to combine multiple aptamers 
and proteins on the same DNA nanostructure for detection using the atomic force 
microscopy (AFM) at the single-molecule level along with methods such as 
electrochemistry at the bulk solution level. Recently it was reported that by 
decorating both aptamers and enzymes to the surface of DNA nanostructure, an 
electrochemical cocaine sensor could be built for sensitive detection of cocaine 
levels,38 where it could facilitate aptamer-cocaine binding at the surface, 
rendering the electrode surface protein-resistant. Therefore, such a device could 
potentially be used to detect cocaine levels in human serum. 
Another example is using QD decorated DNA nanostructure to detect 
cancer cells by fluorescence imaging. Researchers have developed an 
extracellular supramolecular reticular DNA-quantum dot sheath using the self-
assembled DNA network containing cancer cell recoginizing apatmers.39 For such 
platforms, the cancer cells were first recognized and enwrapped by the aptamers 
on the DNA sheath, and then quantum dots linked with single stranded DNA are 
incorporated to the DNA sheath, allowing the cancer cells to fluorescence. 
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Because of the high quantum yield and high local concentration of quantum dots, 
this detection strategy is highly sensitive.   
Besides building nanostructures in a well-defined manner, DNA 
molecules can also be used to create reconfigurable nanomachines, which can be 
driven by stimuli from the environment, such as pH change or ionic strength 
change, and therefore could be used for detecting the presence or level of those 
stimuli in the environment. Such nanomachines can be dated back to 1999, when 
Seeman and co-workers built a DX-tile based device containing a double-stranded 
d(CG)10 linker in-between40, which at high ionic concentration could be converted 
from B-DNA to left-handed Z-DNA and thus creating a rotational motion to 
change the relative position of the two DX tiles. Since then, various DNA 
nanomachines have been built, such as DNA tweezers driven by hybridization of 
complementary strands41,42 or catalyst DNA42,43, G-rich quadruplex44, and i-
motifs45,46. In recent years, with interdisciplinary research on DNA computing, 
there are a series of DNA logic gates constructed and built into larger scale DNA 
circuits47-51, which could release corresponding output signals upon receiving 
different input signals, usually input DNA strands. Those DNA nanomachines 
could be employed in the detection of various targets, such as fragments of DNA 
or RNA, pH change, or various metal ion. Because of the single-molecule nature 
of these nanomachines, it is theoretically able to recognize even single-molecule 
changes of environmental stimuli, making it potentially a very sensitive detection 
device. 
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In addition to the targeting modules described above, development of 
DNA nanostructures for signal amplification also renders the signal detection 
more sensitive. Many of those signal amplification nanostructures have been 
described as “signal transducing modules”. One example is the development of 
hybridization chain reaction (HCR),52 where two species of metastable DNA 
hairpins exist independently in the solution until an initiator strand is introduced, 
and the initiator strand can trigger a cascade of hybridization chain reaction 
between the two hairpins, therefore amplifying the signal multiple folds. As a 
reaction driven by entropy, HCR has been widely used in the detection and signal 
amplification of cellular information, such as in logic gates49,53 and DNA catalyst 
networks54. An in situ diagnostic device was developed in a zebrafish embryo 
model based on HCR,55 where in combination with the fluorophore-labeled DNA 
strands, HCR amplifiers were very suited for sample penetration and yielded high 
signal-to-background ratio. It was also reported that an HCR-based RNA device 
could be used for both detection of cancer cells, and the selective killing of the 
cancer cells by the activated immune response.55,56 Those results demonstrated the 
possibility of combining the diagnostic DNA nanostructures with the disease 
treatment modules, thereby further utilizing the programmability and modularity 
of DNA nanostructures.  
With the construction of the recognition and signaling modules, 
combining the function of both types of modules by simple annealing different 
DNA structures together could further highlight the programmability benefits of 
the DNA nano-designs. One simple example is the DNA molecular beacon, which 
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is a conformation switchable DNA probes. It contains both the recognition portion 
that is usually an aptamer, and the reporter, also known as the signaling 
component that could be either conjugated to a fluorophore or a QD and its 
corresponding quencher. The reporter portion would release itssignal only when 
the recognition portion detects the target molecule and trigger the molecular 
beacon to undergo a structural conformational change, thus reducing the detection 
background and increase the signal/noise ratio. One demonstration of this concept 
was in vivo detection of pH change by combining a pH-sensitive i-motif with the 
FRET fluorophores on a DNA tweezer57. Another example is the DNA circuits 
built by combining multiple DNA logic gates49,53, in which the strand 
displacement by fuel strands serve as the recognition part, and the output strand 
with fluorescence give the output signals. In combination with other 
nanomachines such as i-motifs, the molecular beacon and DNA circuits could also 
be utilized to detect the presence of different target molecules.  
A recent example of multiplexing detection DNA platforms is the 
geometrically encoded fluorescent barcode system self-assembled from DNA.58 
The scientists extend multiple zones on the main body of barcode, which is a 
DNA nanorod, with single stranded DNA of various sequences. Target 
recognition is achieved by hybridization of fluorophore-labeled strands that are 
complementary to the extended staples, and the output signal is decoded by 
detecting epifluorescence or through total internal reflection fluorescence (TIRF) 
microscopy. Application of this DNA barcode system was investigated by 
modifying the barcode with functional ligands, the polyclonal antibodies specific 
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to wild-type yeast, and a proof-of-concept experiment which showed that the 
barcode system could tag those wild-type yeasts cells through the binding 
between the polyclonal antibodies (different bars on the barcode main body) and 
yeast surface receptors (target molecules), that indicated the potential of this 
system for future biomedical diagnostic applications such as in situ labeling and 
detection.          
While most of the above-mentioned DNA nanostructures are used for in 
situ detection or detection of molecules on cell surface, it would benefit the 
disease diagnosis if the DNA nanostructures could detect signals inside the cells. 
Turberfield’s group first showed that a tetrahedron-shaped DNA cage could get 
into the cultured mammalian cells in vitro and localize to the cytoplasm without 
the aid of transfection reagents59, in addition to which Fan’s group further 
demonstrated that a series of logic gates could be constructed on the tetrahedron 
DNA cage by introducing reconfigurable DNA structures such as i-motif, and 
used for intracellular sensing of various signals, including mercury ions, small 
molecules such as ATP, and short strands of DNA.60 Those intracellular logic 
gates used fluorescence as the output signal, making it fast and sensitive for 
detection. The abnormality of ATP level is seen in some metabolic diseases such 
as metalolic myopathies61, and elevated mercury level indicates mercury 
poisoning or related to diagnosis of autism61,62 , therefore such intracellular DNA-
logic gate platforms could potentially be useful tool for disease diagnosis. 
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1.2.2 Functionalized DNA nanostructures for disease treatment   
 Functionalized DNA nanostructures are also employed as carriers to 
deliver various anti-cancer drugs, proteins, and nucleic acids specifically to the 
disease tissue and to maximize the solubility and decreasing clearance to them. 
For example, they have been designed as hollow cages to encapsulate 
nanoparticles63, proteins64, or as cargoes used to display molecules outside65, or 
simply as a carrier to load drugs66. Meanwhile, as DNA can be built into 
reconfigurable nanomachines22,64, it is expected that DNA nanostructures could be 
constructed into controllable drug-release vehicles.  
In a DNA nano-cage, the molecules to be delivered can be protected from 
the degrading or degenerating signal from the serum environment, while small 
molecules such as salt, or substrate could pass through the spaces between DNA 
helices, thus maintaining the catalytic or pharmaceutical activity of the drug. Such 
protection is especially effective in vivo, since there are enzymes, antibodies, or 
other factors that will help eliminate the drug from the blood circulation. 
Moreover, different DNA cargos that can open/close upon external or internal 
stimuli have been developed22,64, rendering it possible to deliver a drug in a 
controllable manner. For example, a logic-gated nanorobot was reported to be 
able to open the cargo, and transport the loaded antibody to its target cell upon the 
addition of the “key”signal, and demonstrated its ability to interface with the 
cells to stimulate the signaling in inhibiting and/or activation of cell growth64. 
As mentioned in the section of disease diagnosis, DNA nanostructures 
have been modified with many nucleic acids, including aptamers and anti-sense 
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RNA, as the recognition molecules. Since it has been demonstrated that aptamers 
function in various biological events including ligands as an agonist or antagonist, 
it is reasonable to expect some functions of disease treatment from aptamer-
modified DNA nanostructures.  
Recently a general RNA motif was selected, which could directly 
internalize into mammalian cells without conventional transfection reagents.67 
Although the underlying mechanism still remains to be explored, such cell-
penetrating RNA motifs may lead to the development of universal nucleic acid 
cell delivery reagents, which would benefit the research of drug delivery. Such 
RNA motifs may be linked to DNA or RNA structures to direct their delivery to 
the cells without conjugation of the conventional cell-penetrating peptides or 
without transfection reagents that are potentially harmful to the cell. The rationale 
underlying the importance of directed cellular delivery is that various disease 
treating reagents could function specifically in certain diseased cell, instead of 
systemic functioning in normal healthy cell as well. And DNA is a negatively 
charged molecule, which was previously thought to be more difficult to be 
delivered to the cells than the positively charged or uncharged molecules, since 
the cell membrane is also slightly negatively charged. There are a host of 
commercially available transfection reagents that have been developed to deliver 
double-stranded DNA or plasmid inside the cells, especially into the nucleus. 
However, it is also well accepted that the cellular delivery of foreign particles 
depends on many parameters, including size, shape, charge, 
hydrophobicity/hydrophilicity, and possible receptor interactions. While the 
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strategy on cell-penetrating RNA motifs still remains to be explored, there are 
many studies that utilize the unique structural and geometrical features of DNA 
nanostructures to deliver special DNA or RNA molecules inside the cells, such as 
CpG oligonucleotide (ODN) linked to a tetrahedron-shaped DNA scaffold 
delivered to immune cells that subsequently activate the cytokine production in 
those immune cells68,69, and delivery of siRNA both in vitro and in vivo for 
regulation of protein expression70. 
Of all the diseases that researchers are developing weapons against, 
malignant tumors are one most common targets. The most traditional treatment of 
tumors is surgical removal and chemotherapy. Various chemotherapy drugs have 
been extensively used in clinical trials and the FDA has approved several 
chemotherapy drugs, such as capecitabine (Xeloda, Roche), doxorubicin 
(Adriamycin, Rubex), mitomycin-C (Mutamycin, Bristol-Myers Squibb) and 
cisplatin (Platinol, Bristol-Myers Squibb) for human use. While many drugs are 
proven to be effective in suppressing the metastasis of tumors, some patients 
develop resistance against some chemotherapy drugs.71 Using nanoparticles as the 
delivery cargo could significantly increase the drug payload and enhance the 
killing effect72,73. And there have been extensive studies that use nanoparticles to 
deliver anti-cancer drugs72,73. However, it was observed that many of those 
nanoparticles face problems such as slow drug release rate, or long-term toxicity 
due to the accumulation of the nanoparticles. Recently researchers investigated 
the possibility of loading anti-cancer drugs to DNA nanostructures as a“Trojan 
horse”, and observed high drug delivery efficiency, rapid drug release inside 
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cells, and reduced drug-resistance in vitro.66 It was previously shown that Doxil 
(Ortho Biotech), a PEGylated liposomal formulation of doxorubicin, served as a 
nanoparticle-drug delivery system and has been used clinically for over two 
decades72, and researchers also demonstrated that a DNA-capped gold 
nanoparticle could be used for doxorubin drug delivery.73 Compared to polymeric 
or metal nanoparticles, DNA nanostructures preserve the advantage of a high 
payload, as it is a compact vessel with high surface to volume ratio and the DNA 
origami structure offers multiple layers of DNA double helices that providea large 
number of docking sites for the interaction of the drug; and it is shown that DNA 
molecules do not exhibit any obvious cytotoxicity by metabolism-based 
assays66,68. They are also able to counterbalances the enzymatic degradation effect 
from the culture medium or potentially patient serum. Moreover, it was shown 
that the structures play a role in the inhibition of the lysosomal acidification, 
which was considered to be contributor to drug-resistance66, in the drug-resistant 
cell line. This indicates it serves a role that function as more than just a drug cargo. 
Another application of this technique on disease treatment relies on its 
ability to self-assemble into larger pieces of DNA nano-sheaths, where it could be 
used as a macromolecular scaffold to direct the assembly of larger particles or 
even the cells. The construction of the artificial matrix that mimic the structure 
and function of the natural extracellular matrix (ECM) has been a challenge for 
tissue engineering, since it is difficult to direct the cells with highly specific three-
dimensional configuration and to replicate the biological sigaling factors that 
naturally exist in the ECM. Researchers have been using biodegradable polymeric 
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hydrogels74, nanofibrillar synthetic biomaterials,75 and PEG-modified materials to 
reconstitute cell adhesion and cell proliferation ex vivo. However, due to the 
intrinsic shortcoming of specificity for those polymeric materials, and there has 
been an emerging need for artificial scaffolds that are structurally programmable 
and addressable, for which DNA has proven to be ideal. It can easily be modified 
with different types of recognition molecules such as proteins or peptides, both of 
which are components of common signaling factors in natural tissues. As a 
biological material, DNA exists naturally in the human body, and is 
biocompatible and biodegradable. Because of this, researchers have explored the 
use of DNA nanostructures to build DNA/protein-based matrices (ECMDP) where 
one-dimensional DNA ribbon structures were functionalized with the proteins 
containing the RGD domain of human fibronectin, the cytoskeletal protein 
elements, and found this ECMDP can be used for ex vivo cellular scaffolds to 
direct cellular attachment, survival, and growth76. Moreover, it was also 
demonstrated to have the capacity to fine-tune cell morphology, cytoskeletal 
organization, signal transduction, and transcription factor localization. Although 
there are still limitations, such as difficulty to scale-up the overall dimensions of 
DNA nanostructures, the above strategy could be further explored to construct 
two-, or even three-dimensional ECMDP, which could potentially lead to the 
creation of higher ordered artificial tissues or even artificial organs. 
Similar to the artificial extracellular matrix, these scaffolds can also 
induce or reconstitute the artificial cell-cell signaling network with the surface 
modification of corresponding signaling molecules. In nature, cell signaling 
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mostly relies on the signaling protein network, such as the ligan/receptor on cell 
surfaces, or enzyme/substrate complexes. However, there are circumstances when 
the expression of ligand/receptor is abnormal or diminished, or the local distance 
between enzymes and substrates are too far away from each other, thereby 
resulting in decreased or inhibited catalytic activity. The conventional way to 
overcome those circumstances is to use molecular cell biology methods to 
reconstitute the ligand/receptor expression level, or use chemical modifications on 
the cell surface to induce artificial cell-cell interactions, or use the polymeric 
materials such as polymeric hydrogels or liposomes to direct the local delivery of 
enzymes or substrates. Those above-mentioned methods have been proven 
effective in some circumstances, but are limited to the availability of cDNA 
library, difficulty and tedium to construct different types of chemical 
modifications, or the lack of specificity in delivery. DNA nanotechnology has 
showed its advantage under those conditions. For example, it was demonstrated 
that different types of cells can be brought together for cell-signaling and creating 
three-dimensional cell clusters by coupling complimentary DNA strands onto the 
surface of various types of cells77; moreover, by incorporating aptamers onto the 
nanostructures, we have achieved the induction of specific cell-cell interactions in 
vitro.78 Recently, the bispecifc aptamers created by double-stranded DNA were 
demonstrated in vivo for their role in inducing immune responses against tumors 
79, highlighting the potential of DNA-scaffolded multi-specific aptamer for 
therapeutic application. 
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1.2.3 Toxicity of DNA nanostructures 
The safety of DNA nanostructures has to be evaluated before being used 
in vivo. Although DNA is a biological material and is considered biocompatible 
and biodegradable, these nano-designs might still be potentially harmful to human 
health, because of their unnatural nature in the formation of unique architectures. 
One possibility of such a harmful phenomenon is induced by the small size of 
DNA nanostructure. It is believed that particles on the nano-scale has a strong 
capacity to penetrate deep into the biological tissues and disrupt their biological 
functions.80 The capacity of DNA nanostructures to direct biological molecules 
into the cells made it an excellent drug delivery cargo. There also have been 
investigations about the influence of DNA nanostructures on cell viability. While 
such influence might not be restricted to cellular metabolism, none of those 
studies detected any cytotoxicity of the structures.66,68,81 
 Another potential harm could be that an in vivo immune response mounted 
against the DNA nanostructure, since any such response could lead to severe 
autoimmune diseases82. We recently demonstrated that no antibody response was 
detected against the double-stranded DNA or DNA nanostructures using a mouse 
model system83, indicating that it might be safe to use them for in vivo 
applications.  
 Finally, there might be a possibility that fragments of the DNA designs 
could enter the nucleus and get integrated into the genome. Although the 
possibility is remote, there could potentially cause genome instability. While there 
have not been any reported systemic investigations on this topic, we may be able 
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to get some information from the in vivo application of aptamers. There are 
several FDA-approved aptamers in clinical use84 or in clinical trials, 85 and most 
of them have been shown to have good safety profiles. There have not been any 
reports on aptamers integrating into the host genome. Although aptamers and 
DNA nanostructures share the same nucleic acid nature, the latter is much larger 
than the former. Given the big size, complexity and diversity of strand sequences 
in the DNA scaffolds, more thorough studies on its in vivo safety are needed in 
the future. 
 
1.2.4 Summary 
DNA nanotechnology has opened up a broad area for applications in 
nanomedince. Although still preliminary, compared to other nanomaterials, DNA 
nanostructures have already shown their potential for disease diagnosis, treatment 
and prevention. With the development in the construction and scaling-up strategy 
of DNA nanostructures, as well as more attention onto their functionalization, it is 
expected that more and more biomedical DNA nanodevices will be constructed 
and explored for clinical usage. Imagine a brand new biomedical world with 
many of the programmable, “ smart”  DNA nano-devices operating and 
detecting in the nano-scale. They could revolutionize the way people diagnose, 
treat and prevent disease, thereby making a brighter future for human health.  
1.3 History of Immunology and immune response principles 
The term “immune” comes from the latin word immunis, which means “to 
make safe”. During the development of medical treatment for diseases, people of 
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various cultures have had different opinions about the origin of diseases. In the 
western society, Edward Jenner first developed the immunization process in the 
late 18th century86. He treated patients with the relatively mild disease of cowpox, 
and observed protection of them from the often-fatal disease of smallpox, while in 
China a previous similar medical procedure called variolation was established in 
the 10th century86, where dried smallpox scabs were blown into the nose and 
served to apparently make people immunized to smallpox. 
While Jenner introduced the concept and initial practice of vaccination, people 
at that time did not know what the infectious agents that cause disease were. It 
was not until the late 19th century when Robert Koch proved that infectious 
diseases are actually caused by microorganisms87, and subsequently, Louis 
Pasteur developed the germ theory of disease87. Those findings expanded Jenner’s 
theory, as well as the investigation on vaccination, and Pasteur developed 
attenuated vaccine to anthrax in 188187; Emil von Behring used anti-toxic agents 
to treat diphtheria patients in 189087.  
Now it is well accepted that the immune system consists of two functional 
components: the non-specific innate immune system, and the specific adaptive 
immune system. The innate immune system is a fast-reacting system, but does not 
generate memory to repeated infection. It fights against the infectious pathogen, 
or pathogen components by various physical (such as skin and mucosa), 
biochemical (such as lysozymes and complement) and cellular (phagocytes such 
as macrophages and neutrophils) barriers. On the other hand, the adaptive 
immune response is slower compared to innate response, but it can generate 
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memory responses against the pathogen upon repeated exposure. It fights against 
the pathogen by various types of cells and molecules, among which the 
lymphocytes and immunoglobulin are two key components. The lymphocytes 
include three types of cells： B cells, helper T cells, and cytotoxic T cells. All 
lymphocytes have surface receptors that bind to antigens, with one cell 
recognizing only one antigen. B cells secrete proteins that can specifically bind to 
foreign molecules such as non-native proteins. Those secreted proteins are termed 
“antibodies”, while the foreign molecule is termed as an “antigen”. Scientists 
recognized the antibodies in 1930, while 30 years before that Paul Ehrlich et al. 
87recognized that a specific antigen could elicit the production of specific 
molecules, later termed “antibody”. 
Vaccines protect people from infectious pathogens by stimulating the host 
immune system to generate specific antibodies against the pathogen. Antibody 
molecules have two distinct functions: one is to specifically bind to the pathogen 
molecules, and the other is to recruit other cells and/or molecules to destroy the 
pathogen after the antibody binds to it. Corresponding to those two functions, the 
structural part carrying those functions are separate from each other in the 
antibody molecule. The antibody molecule is roughly a Y-shaped molecule, with 
the top two arms responsible for binding to the antigen, and the bottom stem 
responsible for the recruitment of the effecter. As shown in Figure 1.3, the region 
on antibodies where it interacts with the antigen is called the “paratope”, while the 
region on the antigen interacting with the antibody is called epitope. The variety 
of paratope is generated from a highly-organized recombination process, V(D)J 
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recombination, and in theory more than 1011 different types of paratopes could be 
generated87. This antibody repertoire provides the material basis for generating 
antibody binding to virtually any type of antigen.  
 
Figure 1.3 Schematic illustration of antigen-antibody interaction. The antibody 
molecule contains the Fab portion (top arm of the Y-shape) and the Fc portion 
(bottom stem of the Y-shape). The end of Fab portion (paratope, drawn in green 
and light green) is highly variable and responsible for antigen binding, and the 
part of the antigen that is bound by the antibody is named as epitope. 
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Antibody response is one of the responses generated upon pathogen infection; 
however the host immune system sometimes fails to mount effective antibody 
response. Adjuvant is a type of immune-stimulating agent to boost immune 
response, especially when the antigen per se is not enough to induce antibody 
response. Commonly used adjuvants include aluminum, oil emulsion, and 
virosomes. The adjuvants stimulate the immune system by mimicking the 
pathogen-associated molecular patterns (PAMPs) to activate the innate systems, 
because the innate immune system has evolved to recongnize those PAMPs. 
PAMPs include lipopolysaccharide (LPS), double-stranded RNA (dsRNA), 
single-stranded RNA (ssRNA), unmethylated CpG dinucleotide-containing DNA 
(CpG ODN), bacterial flagellin, etc. The innate immune system recognizes the 
PAMPs by a group of special receptors named Toll-like receptors (TLR), with 
each TLR specializing in the recognization of certain PAMPs (Figure 1.4). Upon 
activation of the innate immune system, the communication between the innate 
and adaptive immune systems transduce the activation signal to the lymphocytes, 
thereby inducing enhancement of the adaptive responses. 
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Figure 1.4 Interactions between TLRs and PAMPs. Common TLRs and their 
corresponding PAMP ligands are shown. PAMPs from a bacterial source, such as 
flagellin, LPS, and CpG ODN interact with TLR-5, TLR-4, and TLR-9, 
respectively. PAMPs from a viral source, such as endosomal ssRNA or 
extracellular dsRNA, bind to TLR-7 and TLR-3, respectively. It is worth noting 
that TLR-3, TLR-7 and TLR-9 are on the endosome membrane, while the other 
TLRs are on the cell membrane. 
  24 
 
Figure 1.5 General mechanism of innate and adaptive response triggered by CpG 
ODN. Antigen presenting cells (APC) including B cell, macrophages, and 
dendritic cells internalized CpG ODN are activated, thereby transducing 
activation signals to Th0 cells. The Th0 cells are differentiated to the Th1 cell 
upon the activation signal from APC, and subsequently stimulate the antibody 
production in plasma cells, or the maturation of naïve CD8+ cells into cytotoxic T 
cells, or release cytokine such interferon-gamma (IFN-γ). In summary, CpG ODN 
stimulates the function of APC and therefore facilitates the generation of both 
humoral and cellular immune responses. This figure is adapted from the 
literature.88 
 
Although mentioned as two types of immune responses, the innate response and 
adaptive response work together to mount effective response against foreign 
antigens. One example of such cooperation is the immune response against the 
CpG ODN, as shown in Figure 1.5. Adjuvants such as CpG interact with TLRs of 
the antigen presenting cells, including B cells, macrophages, dendritic cells and 
activate those APCs, which initiates an immunostimulatory cascade. One of the 
activation results is to promote the T cell maturation. The CpG adjuvant enhances 
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the antigen presentation capacity of APC, and therefore, Th0 cells is matured into 
Th1 cells, which subsequently induce the proliferation of plasma B cells and its 
antibody production, as well as the production of cytokines such as IFN-γ or 
helping in the maturation of naïve CD8+ cells into cytotoxic T cells that directly 
carry out the killing activity. As shown in Figure 1.5, this process involves cells 
and signals from innate immune response all the way to the adaptive response, 
and this crosstalk between innate and adaptive response directs them to work 
together against pathogenic infections. 
 Specifically for antibody production, T-cell dependent B cell response is 
more effective and it requires cognate interaction between Th cells and B cells, as 
shown in Figure 1.6. 
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Figure 1.6 T-cell dependent B cell responses. Two types of signals are required 
for activating the B cell. The first signal (marked as 1 in the graph) is from the 
antigen crosslinking of B cell receptors (BCR); and the second signal (marked as 
2 in the graph) is from the interaction between MHC molecule (yellow)-presented 
epitope (red) and its corresponding T cell receptors (blue), as well as the 
interaction between CD40 on B cell and CD40L on the helper T cells. Such 
cognate interactions induce the release of cytokine from Th cell, which will 
subsequently activate B cell for antibody production. 
 
Another cooperative phenomenon between adaptive and innate response, is the 
NK cell mediated killing. This process is also known as antibody-dependent 
cytotoxicity, as shown in Figure 1.7. NK cell is one of the important cells 
involved in the innate response. They contain small granules in the cytoplasm that 
are cytotoxic, and once those cytotoxic components are released, the other cells in 
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close proximity will be killed. The specific killing of tumor cells, or other 
pathogen-infected cells, are mediated by a pathway known as antibody-dependent 
cell-mediated specific cytotoxicity (ADCC). Tumor cells or pathogen-infected 
cells, such as macrophages, are bound by antibodies produced by the host, while 
exposing the Fc portion outside. The NK cell contains Fc receptors that can 
specifically bind to the Fc portion, and therefore the antibody-bound tumor cells 
will be brought within close proximity of NK cells. Concurrently, multivalent Fc 
portions on the tumor cells induce the crosslinking of the Fc receptors, activating 
the NK cells to release granules and therefore kill the tumor cells.  
Figure 1.7 Antibody-dependent cell-mediated cytotoxicity. 87 
1.4 Projects: potential of DNA nanostructures for vaccine development and 
targeted cell-cell interactions 
 
Based upon the body of work discussed above, two main categories of 
vaccines have been developed. The first category is to use the whole pathogenic 
microorganism, such as attenuated vaccines. Those vaccines usually induce strong 
immune response, but suffer from safety issues due to mutations of pathogen back 
to the disease-causing form91; the other category has been developed with the 
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progress of molecular biology, where a protein subunit, part of the pathogen 
rather than the whole-agent, is used to induce the immune response91. While the 
latter strategy has been shown to be safe since it does not contain any genetic 
material of the pathogen or any disease-causing components, it is usually not 
efficient enough to induce strong immune response, and therefore requires 
multiple immunizations, higher dose, and/or in combination with adjuvants91.  
To enhance the immunogenicity of subunit vaccines, researchers have shown 
that bringing the antigen and adjuvant to close proximity or linking them together, 
could boost the immune responses89, and there are various platforms for 
connection, such as encapsulation within polymeric nanoparticles90,91,viral-like 
particles91,92, and covalent linkage to protein carriers93. While proven effective in 
many cases, those connection methods are either short of control on the spatial 
arrangement of immunogenic molecules or face technical challenges for 
construction of stable and functional vaccine complexes. 
As mentioned in the above section 1.2, DNA nanostructures provide an ideal 
platform for the rational design of vaccines. First, with the recent development of 
conjugation techniques, it is now feasible to link different types of molecules to 
DNA either covalently or noncovalently, without compromising their originally 
designed functions. Second, by careful design of DNA strand sequences, it is 
convenient to put the immunogenic molecules to either present themselves on the 
surface or within the DNA nanostructure. By doing this, it is a well-suited system 
for the construction of multivalent epitopes with defined distance and 
configuration for B cell receprot (BCR) crosslinking and B cell activation. This 
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could significantly benefit the delivery of molecules such as adjuvants to specific 
cells and possibly control the release of them or other immunogenic molecules 
inside APCs, reducing the non-specific activation of other cells as well as 
avoiding the unwanted inflammations. Lastly, in combination with other 
nanomaterials, it is possible to elongate the serum half-life of these DNA 
nanostructure-based vaccines and therefore enhance their delivery to the lymph 
node, which is a pre-requisite for T/B cell interaction, B cell 
activation/differentiation and antibody production. Taken together, the DNA 
nanostructures could potentially provide an excellent platform for the assembly of 
synthetic vaccines, and my research described here has been to explore the DNA 
nanostructure assembled synthetic vaccines to test their immunogenicity in the 
animal model. 
At the same time, as mentioned in the description about immune responses, 
specific cell-cell interactions are required in various immunological events, such 
as interactions between T cell and macrophages, T cell and B cell, NK cell and 
tumor cell and so on. The immune system would be compromised when the 
targeted cell-cell interactions are defective or diminished. By employing the 
aptamer-DNA platform, we constructed multivalent bispecific aptamer complexes 
to induce cell-cell interactions, in the interest of applying this strategy to induce 
those above-mentioned cellular interactions. 
The cell-cell interaction that is mediated by DNA scaffolded multivalent bi-
spepcifc aptamers is described in Chapter 2, and the construction of synthetic 
model vaccines based on them is explored and described in Chapter 3. 
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Furthermore, a DNA scaffolded nicotine vaccine is developed, and its in vivo 
function is outlined in Chapter 4.  
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Chapter 2 
TARGETED CELL–CELL INTERACTIONS BY DNA NANOSCAFFOLD-
TEMPLATED MULTIVALENT BISPECIFIC APTAMERS 
Adapted with permission from Liu, X., Yan, H., Liu, Y., Chang Y.; Targeted cell-
cell interactions by DNA nanoscaffold-templated multivalent bispeficic aptamers, 
Small, 2011, 7, 1673-1682. Copyright 2011 John Wiley and Sons, Inc. 
Author contributions: Liu Y. and Chang Y. conceived the project, Liu, X., Yan, 
H., Liu, Y., and Chang Y. designed the experiments, Liu X. performed the 
experiments and wrote the manuscript, Yan H., Liu Y., Chang Y. edited the 
manuscript and Flores C. proofread the manuscript. 
 
2.1 Abstract 
Cell–cell interactions are essential for multicellular organisms, playing 
important roles in their development, function, and immunity. Herein a bottom-up 
strategy to construct self-assembled DNA nanostructures is reported, consisting of 
multivalent, bispecific, cell- targeting aptamers to specifically induce cell–cell 
interactions. Various DNA nanoscaffolds are rationally designed to assemble 
aptamers with different valencies and flexibilities, and their cellular binding 
capabilities are tested. Multivalent aptamers, assembled on more rigid scaffolds, 
display higher binding activities. Further, multivalent bispecific aptamer fusion 
molecules are constructed based on this configuration, and successfully link two 
types of cells. Using cell-targeting aptamers, the presented strategy eliminates the 
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need to chemically modify cell surfaces and offers excellent cell specificity, 
binding efficiency, and stability. This proof-of-concept study establishes that 
multivalent bispecific aptamers linked on DNA-nanoscaffolds can mediate 
cellular engagement, which could lead to their use in directing or guiding cell–cell 
interactions in many biological events. 
2.2 Introduction 
Cell-cell interactions are fundamental biological processes within 
multicellular organisms that are critical to their development, the formation of 3D 
tissue/organ structures inter- and extra-cellular communication, and immunity.1 
An array of surface molecules is involved in mediating cell-cell interactions, 
including nonspecific adhesion molecules and specific pairs of receptors/ligands.2 
Cells can also be glued by, and trapped within, the extracellular matrix.2 
Extensive efforts have been devoted to recapitulate cell-cell interactions ex vivo, 
for tissue engineering and organ reconstruction, by employing various synthetic 
products.3,4 Considerable progress has been made toward defining interactions 
between cells using bottom-up strategies, such as layer-by-layer printing,5 
directed assembly using dielectrophoretic forces,6,7 or NIR lasers (700-1000 
nm).8-11 In addition, cells may be linked through hybridization between 
complementary DNA molecules attached to cell surfaces.12 Although layer-by-
layer printing has been shown to create 2D and 3D patterns of living eukaryotic 
cells on surfaces pretreated with specific matrices, this approach relies on 
adhesive molecules displayed on the cell surface,5 which limits its application to 
only the cells bearing these molecules. Similarly, the directed assembly of 3D 
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structures by dielectrophoretic forces 6,7 or lasers 8-11also depends on nonspecific 
gluing materials, e.g., polymerizable hydrogels. 
Although the above strategies are excellent in building artificial tissues via 
controlled assembly, they are nonspecific in nature and, thereby, not suitable for 
recapitulating specific cell-cell interactions. Specific cell–cell interactions are 
mediated by ligands on one type of cell engaging with their specific receptors on 
another type of cell, which is best exemplified at various stages of the immune 
response, including antigen recognition, immune cell activation, and target 
elimination.1 Although the specific ligand/receptor pairs dictate which types of 
cells can interact with one another, the spectrum of cellular interactions can be 
artificially broadened by applying surface-molecule targeting agents. For 
example, bispecific antibodies (Bi-Abs),13-18 in which two different specific 
antigen binding motifs are engineered covalently onto the same molecule, can 
direct an interaction between two types of cells that lack appropriate 
receptor/ligand pairs for their engagement. Thus, Bi-Abs have been explored to 
direct immune cells toward target-specific tumor cells for their specific 
destruction. 13-18  Although the Bi-Ab approach is very promising, the genetic 
engineering of Bi-Ab molecules to retain their stability and functionality through 
appropriate folding could be technically challenging.13,17 In addition, the 
generation of novel Bi-Abs may be restricted by the availability of existing 
cDNAs coding for the antibodies of interest. Finally, the immunogenicity of 
engineered Bi-Abs also limits their applications in vivo.19 Therefore, there is still a 
need for alternative strategies to induce specific cell-cell interactions, with 
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minimal chemical modifications to the cells and fewer immunogenic problems to 
the host. 
Here, a new bottom-up strategy is developed using bispecific aptamers 
linked onto DNA nanoscaffolds to bring two types of cells together. This strategy 
utilizes aptamers as recognition molecules directly targeting the cell surface, 
eliminating the need to chemically modify cell surfaces, and it shows excellent 
cell-targeting specificity, binding efficiency, and stability. Aptamers, also 
regarded as ‘chemical antibodies’, are single-stranded nucleic acids that can be 
selected, in vitro, to specifically bind to a variety of targets, from small chemical 
compounds to complex proteins and even cells.20-22 Theoretically, aptamers can 
be isolated from combinatorial libraries against any target of interest through an 
in-vitro method known as systemic evolution of ligands by exponential 
enrichment (SELEX).20-22 Unlike antibodies, aptamers can be easily chemically 
synthesized and offer significant advantages over antibodies, such as a broad 
target range, low cost, and animal-free production.23 Furthermore, due to the 
nucleic acid nature of aptamers, they are less immunogenic compared to 
antibodies, and may be more practical for in vivo applications.23 
In many instances, aptamers have been utilized in molecular 
detection/delivery platforms,24,25 or as biosensors to identify and sort specific 
types of cells out of a mixture.26 However, aptamer binding affinities are usually 
lower than those of antibody–antigen interactions.23 Multivalent aptamers have 
been shown to possess increased binding activities when covalently linked to 
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nanoparticles27 or liposomes28,  even when their distributions and orientations 
have not been deliberately controlled. It is possible that some scaffold-bound 
aptamers might not effectively contribute to binding due to steric hindrance and 
mismatched orientations between aptamers and their target entities. Since cells 
have large surface areas and the identities and distributions of the binding entities 
for aptamers tend to be unclear, we propose that the distribution and orientation of 
each aptamer unit in a multivalent aptamer may be controlled and optimized to 
achieve maximal binding efficiencies. 
Since Seeman’s vision of using DNA as a structural material based on the 
simple rules of Watson-Crick base-pairing, 29 DNA self-assembly has opened up a 
new paradigm to study inter- and intra-molecular interactions. 30 Due to the fact 
that DNA can be functionalized by various chemical conjugation strategies, DNA 
nanostructures have been used as scaffolds to organize and pattern other 
molecular species, such as proteins31-33 and nanoparticles,34,35 with precisely 
controlled spatial resolution. To construct multivalent aptamer complexes with 
more controllable valence, orientation, and distance between neighboring 
aptamers, we took advantage of the branched DNA nanostructures as scaffolds to 
assemble aptamers at defined positions. Increased binding affinity was observed 
for the multivalent aptamers linked by rigid scaffolds. Furthermore, we designed 
different DNA scaffolds to assemble the more sophisticated bispecific multivalent 
aptamer fusions to engage specific interactions between two different types of 
cells. 
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2.3 Materials and Methods 
2.3.1 DNA annealing 
Stoichiometric ratios of all strands were mixed to a final concentration of 
1µM in 1× TAE Mg2+ buffer (40 mM Tris base, 20 mM acetic acid, 2 mM 
EDTA·Na2·12H2O, 12.5 mM Mg (CH3COO)2·4H2O). The sample was heated to 
95 °C and slowly cooled on ice to 4 °C in 2 hrs. For the multivalent bispecific 
aptamer or its corresponding nonspecific controls, each DNA tile was annealed 
individually first, and the two tiles of the same structure were then mixed and 
annealed from 37°C to 4°C in 3hrs. 
2.3.2 Cell culture conditions                                                                                
Jurkat and Ramos cell lines were maintained in RPMI-1640 medium 
(Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco), penicillin (100 
units mL−1, Invitrogen), 2-methoxyethanol (50 µM) and streptomycin (0.1 mg 
mL−1, Invitrogen), at 37 °C with 5% CO2.  
2.3.3 Fluorescence labeling of the cells 
Ramos cells were incubated with 5 µM MitoSOX™ Red mitochondrial 
superoxide indicator (Invitrogen) in the RPMI-1640 medium for 50 min at 37 °C, 
and Jurkat cells were incubated with 5 µg mL−1 H2DCFDA (2′, 7′-
dichlorodihydrofluorescein diacetate, Invitrogen) in the RPMI-1640 medium for 
10 min at 37 °C. Cells were spun-down by centrifugation at 1500 rpm (380 × g ) 
for 5 min, washed twice with 5-10 mL of binding buffer (6.05 mM MgCl2, 1.2 
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mM CaCl2, 4.5 g L−1 glucose, and 0.2% NaN3 in PBS, pH 7.4) containing 1 mg 
mL−1 tRNA/BSA, and counted by hemocytometer before assembly. For confocal 
microscopy imaging, Ramos cells were prelabeled with CellTracker™ Red 
CMTPX (Invitrogen) and Jurkat cells were prelabeled with CellTracker™ green 
CMFDA (Invitrogen), following the manufacturer’s manual.  
 2.3.4 Analysis of Cell Clusters by Flow Cytometry    
5 × 105 of the MitoSOX-labeled Ramos cells were incubated with 60 nM 
multivalent bispecific aptamers or nonspecific controls in 50 µL binding buffer 
containing 1 mg mL−1 tRNA/BSA for 30 min on ice and washed once with 200µl 
binding buffer. 5 × 106 of H2DCFDA-labeled Jurkat cells were then added to the 
Ramos cell pellet, and the cell mixtures were resuspended and incubated in 50 µL 
binding buffer containing 1 mg mL−1 tRNA/BSA for another 30 min on ice. 
Finally, the cell mixtures were fixed with paraformaldehyde at a final 
concentration of 1% (w/v). Flow cytometry analysis was performed on a BD 
FACSCalibur (BD Biosciences, San Jose, CA) flow cytometer equipped with a 
488 nm argon laser (BD Biosciences, San Jose, CA). Data were analyzed using 
BD CellQuest Pro software (BD Biosciences, San Jose, CA) 
2.3.5 Imaging of Fluorescence Labeled Cells by Confocal Miscroscope  
           5 × 105 of CellTracker™ Red CMTPX-labeled Ramos cells and 5 × 105 of 
CellTracker™ green CMFDA-labeled Jurkat cells were incubated with the 
multivalent bispecific aptamers or nonspecific controls according to the protocol 
described in the section above, ‘Analysis of Cell Clusters by Flow Cytometry’. 
After incubation, the cells were dropped on a microcover glass and observed 
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through a 40 × object under Zeiss confocal microscope (Carl Zeiss, Germany) 
using the following laser settings: HeNe488 (CellTracker™ green CMFDA 
channel), HeNe543 (CellTracker™ red CMTPX channel) and HeNe633 (bright 
field image channel). The Image analysis was performed using LSM5.0 software 
(Carl Zeiss Microimaging, Germany). 
 
2.4 Results 
2.4.1 Binding avidity of multivalent aptamers compared to monovalent aptamers 
The multivalent aptamer-DNA scaffold is formed through nucleotide 
basepairing between designed linkers, scaffold DNA, and the aptamers. Figure 2.1 
illustrates a few representative multivalent aptamer designs used in this study. To 
test the concept, two previously identified aptamers with different cell specificity 
were chosen for the construction of multivalent aptamers on DNA scaffolds. 
These are the TE02 aptamer that binds to Ramos cells (a human B cell line from 
Burkitt’s lymphoma) but not to T cells, 36and the LD201t1 aptamer that binds to l-
selectin present on Jurkat cells (T cell leukemia line) but not to B cells.37 Both 
aptamers possess a KD (dissociation constant) in the nanomolar range to their 
specific target cell surfaces. Flow cytometry results confirmed that the binding of 
each individual aptamer with its target cell is specific (Supporting Information 
(SI), Figure S2.2). 
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The TE02-based multivalent aptamer complex was con- structed by 
adding an additional nucleotide overhang at the 5′ or 3′ end of the TE02 aptamer, 
which is complementary to linkers present in the DNA scaffolds (see oligonucle- 
otide sequences in the SI, Figure S2.1). Bivalent, trivalent, and tetravalent 
aptamer conjugates were generated using linear double-stranded linkers, J1 
junctions,38,39 and 4 × 4 DNA tiles,40 respectively (Figure 2.1). Although 
multivalency has been shown to increase the binding avidity,23,27,41 this may be 
influenced by the local concentrations, the accessibility of adjacent aptamers, 
steric effects of neighboring aptamers on the DNA scaffolds, and the 
conformational flexibility of target molecules on the surfaces of cells. While 
multivalent aptamers with more flexible structures may reduce the steric 
hindrance, an increase in flexibility may also result in more negative entropy 
change upon binding, which leads to a destabilization of their interactions with 
the target cells. To test this effect, flexible, multivalent aptamers were created by 
incorporating a five- or ten-base-long linker (T5 or T10) between the scaffold and 
each aptamer (Figure 2.1). 
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Figure 2.1. Schematic design of representative multivalent aptamers on DNA 
nanostructures. Each single TE02 aptamer is shown as a stem-loop, the flexible 
linkers composed of polythymine bases are shown as single wavy lines, and the 
DNA nanostructures are shown as double- helices. a) Bivalent flexible aptamer 
linked on a linear DNA structure containing two 20 bp (basepair) double-stranded 
arms flanked by a single-stranded five-thymine linker; b) flexible, trivalent 
aptamer linked to a J1-junction structure. The length of each arm is 10 bp, 
aptamer is linked to the end of the DNA arm through a single-stranded five-
thymine linker; c) rigid, tetravalent aptamer linked to a 4×4 DNA tile. 
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Flow cytometry analysis was used to determine the binding activity of 
each constructed multivalent aptamer with their target cells. A competition assay 
was carried out to compare the binding avidity of the bivalent, trivalent, 
tetravalent aptamers of TE02 with different flexibilities specific to Ramos cells, 
after pre-incubation of the cells with the fluorescence-labeled monovalent 
aptamer. Specifically, a fixed amount of fluorescein-labeled monovalent TE02 
(5′6-FAM from Integrated DNA Technologies, CA) was first incubated with 
Ramos cells, and then increasing concentra- tions of unlabeled TE02 of various 
multivalencies were added to the mixture. The multivalent aptamers displace the 
labeled monovalent TE02 from the cell surface in a concentration- dependent 
manner. Based on the flow cytometry analysis, the concentration of each 
unlabeled multivalent aptamers that caused a 50% reduction in the initial 
fluorescence intensity, defined as IC50, was obtained. Figure 2.2 shows the repre- 
sentative binding competition curves and their IC50 values. The aptamer 
structures with lower IC50 values correspond to higher binding avidities. When 
comparing aptamers of the same multivalency but different flexibilities, it is 
interesting to find that both rigid bivalent and rigid trivalent TE02 aptamers 
appear to have higher binding activities than their corresponding flexible ones 
(Figure 2.2b). The rigid tetravalent TE02 linked on a 4×4 DNA tile displayed the 
strongest binding among all the multivalent aptamers tested (IC50 of 6.0 ± 1.2 
nm). This confirms the advantage of tetravalent aptamers in cell binding over the 
monovalent ones. Similarly, an increase in the binding avidity of multivalent 
  51 
LD201t1 aptamers to Jurkat cells was also observed when tetravalent LD201t1 
aptamers were constructed using the same strategy (SI, Figure S2.3b). 
 
Figure 2.2. Binding avidity of the multivalent aptamers compared to the 
monovalent aptamer. a) Representative binding competition curves. Percentage of 
fluorescence intensity is calculated using the following equation:%Fluorescent 
intensity = (MFI of sample - MFI of nonspecific control)/ maximum MFI ⋅ 100%, 
where MFI stands for mean fluorescence intensity. Each percentage of 
fluorescence intensity is the mean value from three parallel experiments; error 
bars represent the standard deviation of the measurements. The thin solid lines are 
the fits to a sigmoidal curve. b) Summary of IC50s obtained by the binding 
  52 
competition assays. Error bar indicates standard deviation from three 
measurements. 
2.4.2 Stability of multivalent aptamer in serum 
The stability of multivalent aptamers assembled on DNA nanoscaffolds is 
critical to the exploration of their in vivo applications, as they are expected to be 
constantly exposed to the nucleases present in extracellular fluids or released from 
intracellular pools. Before the role of aptamer-DNA scaf- folds in mediating cell–
cell interactions was examined, their stability in the presence of nuclease-
containing serum was tested.42 A trivalent TE02 aptamer assembled on a 4 × 4-
tile-based DNA scaffold was prelabeled with DNA-intercalating dye, YoYo-1 
(Invitrogen), to distinguish it from nucleic acids present in the serum. The 
trivalent aptamer was incubated with rabbit serum at a 1:1 volume ratio, at room 
temperature, for various times ranging from 30 min to 2 h (Figure 2.3). A 
fluorescein-labeled, monovalent TE02 aptamer was also set up in a similar 
manner as a control. After incubation, the reaction mixtures were analyzed by 
native polyacrylamide gel electrophoresis (PAGE) to determine the integrity of 
the aptamers, as revealed by fluorescein or YoYo-1 fluorescence (Figure 2.3). It 
was shown that, although the level of intact monovalent aptamers was not 
significantly changed upon incubation with serum, a few faster-migrating bands 
were observed with increase of incubation time (Figure 2.3a), reflecting degrada- 
tion of the monovalent aptamers. Such degradation bands are barely detectable in 
experiments involving the trivalent aptamers (Figure 2.3b), indicating 
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significantly improved sta- bility against nuclease activity when the aptamers are 
linked to a DNA nanostructure. 
 
Figure 2.3. Stability of monovalent and multivalent aptamers upon incubation 
with nuclease containing serum. Fluorescein-labeled aptamers were incubated 
with rabbit serum at a 1:1 ratio (v/v) for 0.5, 1, and 2 h at room temperature, and 
then analyzed by native PAGE. a) 12% PAGE for a monovalent aptamer; b) 7% 
PAGE for a trivalent aptamer on a 4 x  4 tile. The arrows depict the bands for 
monovalent aptamer and the trivalent aptamer, respectively. 
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2.4.3 Rational design of multivalent, bispecific aptamer fusions for cell-cell 
adhesion 
Based on the above results, the rigid tetravalent aptamers were used to construct 
multivalent bispecific aptamers for engaging cell–cell interactions. The two types 
of aptamers chosen had been previously reported to specifically bind to two 
different lymphocyte cell lines: TE02 for Ramos, a B cell line, and LD201t1 for 
Jurket, a T cell line36,37  (SI, Figure S2.2). A bispecific heterooctamer was 
designed based on a dimer of five-point-star tiles, 43 in which a set of four 
aptamers are linked to the end of four arms of each tile, such that one tile contains 
a tetravalent TE02 aptamer and the other tile contains a tetravalent LD201t1 
aptamer. The two tiles are linked together, through the remaining arm that 
contains a complementary 8-bp sticky end (Figure 2.4a). For simplicity, we will 
refer to this structure as a bispecific aptamer fusion. It was first confirmed that 
both tetravalent TE02 and tetravalent LD201t1 aptamers linked to a five-point-
star DNA tile displayed similar binding enhancement factors (≈4-fold decrease of 
IC50 value) towards their target cells, compared to their corresponding 
monovalent aptamers. This behavior is similar to those tetravalent aptamers 
assembled on the 4×4 tiles (SI, Figure S2.3a,b), possibly because the distances 
between adjacent aptamers in both constructs are similar: ≈11 nm in the 4×4 tiles 
and ≈10 nm in the five-point-star tiles. 
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Figure 2.4. Cell–cell interactions induced by multivalent, bispecific aptamers. a) 
Schematic design of the scaffold for multivalent, bispecific aptamers that use a 
dimerized five-point-star DNA tile to bring two tetravalent TE02 and LD201t1 
aptamers together. b) Schematic of the expected cell–cell adhesion mediated by 
the multivalent, bispecific aptamers. c) Flow cytometer staining profile of the two 
individual prelabeled cells. Ramos cells were labeled with MitoSOX red 
mitochondrial superoxide indicator (red) and Jurkat cells were labeled with 
DCFDA (green). d) Flow cytometry analysis of cell mixtures with multivalent 
aptamers. The concentration of multivalent aptamers is 120 nM. Insets: the 
double-labeled cell population was gated out and the FSC/SSC scattering plot was 
compared to that of the whole cell population. The relatively larger size of the 
double-labeled cells implies that they are cell conjugates. e) Control experiments: 
flow cytometer analysis of cell mixtures without any DNA aptamers, or with the 
five-point-star tiles containing 120 nM of a nonspecific, poly-T heterooctamer. 
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To monitor the linkage efficiency between Ramos and Jurkat cells using 
the bispecific aptamer fusion by flow cytometry analysis, these two types of cells 
were prelabeled with cell-permeable, fluorescent vital dyes, i.e., MitoSox™ (red, 
Invitrogen) and H2DCF-DA (green, Invitrogen, see Materials and Methods), to 
obtain uniformly labeled Ramos (red) and Jurkat (green) cells (Figure 2.4c). In 
this way, the Ramos-Jurkat cell conjugates would be identified as a double-
stained cell population. The prelabeled cells were mixed in a ratio of Ramos: 
Jurkat = 1:10 following the protocol described in the Materials and Methods. 
When the bispecific aptamer fusions were added, a double-stained cell population 
appeared in the dot plot of the flow cytometry analysis (Figure 2.4d). The 
percentage of double-stained cell conjugates was calculated by dividing the 
double-stained population over the total population of Ramos cells, i.e. by 
dividing the cell number of the upper right quadrant over the total number of both 
upper left quadrant and upper right quadrant in Figure 2.4d. Compared to the 
negative control, the cell mixture containing no aptamer, or the nonspecific 
control containing octamers of polythymine (same length as the aptamers, linked 
on the dimer of five-point-star), the cell mixture with the bispe- cific aptamer 
fusion showed the highest population of the double-stained cell conjugates, 
≈21.7% of the Ramos cells (Figure 2.4d,e). From the flow cytometry results, it is 
also observed that some of the Jurkat cells were not labeled with green vital dye 
(≈5%), which might result from low metabolisms in a subpopulation of these cells 
(Figure 2.4c). Therefore, the percentage of the double-stained cell conjugates 
calculated is likely underestimated. Moreover, based on the forward scatter (FSC) 
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and side scatter (SSC) analyses for cell sizes, the population of double-stained 
cells (gated by the right upper panel of the dot plot profile in Figure 2.4d) appears 
to belong to a category of cells with relative larger sizes, whereas the whole cell 
population have sizes ranging from small to large. This data provides additional 
support for the formation of Ramos-Jurkat cell conjugates. 
2.4.4 Improved Cell-Cell Interaction Efficiency Mediated by More Stable 
Linkage Between Two Five-Point-Star Tiles 
That the rigid, multivalent aptamers give higher binding avidities than the 
corresponding, more flexible, multivalent ones has now been demonstrated. It is 
interesting to find out how the flexibility or stability of the linkage between two 
tiles in the bispecific aptamer fusions influences the cell-cell interaction 
efficiency. In particular, we sought to determine whether the cell-cell interaction 
efficiency could be improved by varying the stability of the linkage between two 
five-point-star tiles. Bispecific aptamer fusions containing a partial double-
stranded linkage (8-bp double-stranded sticky ends plus a 5 nt (nucleotide) single-
stranded region, designated ‘DS–SS’) or a complete double-strand linkage 
(designated as ‘DS–DS’, an uninterrupted 21 bp) were compared here (Figure 
2.5a). The bispecific aptamer fusions containing DS–DS linkages show a much 
higher percentage of double- stained cell conjugates (37.2% of the Ramos cells, 
Figure 2.5f) than the ones containing DS–SS linkages (22.1% of the Ramos cells, 
Figure 2.5d), while the corresponding nonspecific controls produced much lower 
percentages of double-stained cells (3.1% in DS–SS linkage and 3.6% in DS–DS 
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linkage, Figure 2.5e,g). This result was reproducible with parallel experiments 
(SI, Table S2.1). The stable cell-cell conjugates through the bispecific aptamer 
fusions containing DS–DS linkages were also evident under fluorescence 
confocal microscope (Figure 2.5b). The presence of single-strand DNA in DS-SS 
scaffolds may cause too much flexibility to engage stable cell-cell interactions. 
Alternatively, the single-strand DNA may be more susceptible to the nuclease that 
might be released from incubated cells. This scenario, however, is unlikely, as the 
two DNA structures, after their incubation with the cells, were found at 
comparable levels of integrity (SI, Figure 2.4S). Thus, the better efficacy with the 
DS–DS scaffolds is likely attributed to their improved linkage strength. 
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Figure 2.5. Multivalent, bispecific aptamers with different stabilities and their 
efficiencies for inducing cell-cell interactions. a) Schematics of the scaffold for 
multivalent, bispecific aptamers with different stabilities. Inset shows the 
comparison between the less stable DS–SS linkage and the more stable DS-DS 
linkage. b) Representative confocal images showing cell conjugates using 
multivalent bispecific aptamers with DS-DS linkage. The cell ratio was adjusted 
to 1:1 (Ramos:Jurkat) and fluorescent dyes CellTracker CMFDA and CellTracker 
CMTPX (see Experimental Section) were used for better imaging quality. c) 
Representative confocal microscope images showing minimal cell conjugates 
when no aptamer was added. d-g) Flow cytometry analysis of cell mixtures with 
60 nM DS-SS aptamer, its polythymine control, DS-DS aptamer and its 
polythymine control, respectively. 
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2.4.5 Rearranged, Multivalent, Bispecific Aptamer Fusions Do Not Improve Cell–
Cell Interaction Efficiency 
Potential improvement of the cell–cell interaction effi- ciency was tested 
by increasing the number of each aptamer unit in the bispecific aptamer construct 
when linked onto a DNA scaffold with a different configuration. A linear- 
branched DNA structure was designed that contained thirteen TE02 aptamers on 
one side and thirteen LD201t1 aptamers on the other side (Figure 2.6a). The 
distance between each TE02 or LD201t1 aptamer is ≈10 nm, similar to that in the 
five-point-star tile, and the linkage between the two sides is double-stranded (42 
bp). Flow cytometry results indicate that this linear-branched configuration with 
much increased valency (13 for each aptamer) provides no further increase, and 
even a slightly lower efficiency for inducing cell–cell con- jugates (26.3% of 
Ramos cells, Figure 2.6b), as compared to the dimer with the five-point-star tile 
design (4 valencies per aptamer, 30.5% of Ramos cells, Figure 6d). This data 
indicates that increasing the multivalency beyond 4 in the multivalent bispecific 
aptamers does not necessarily further increase cell-cell interactions. 
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Figure 2.6. Twenty-six-mer, bispecific aptamer linked on linear-branched DNA 
structure and its ability to engage cell-cell interactions. a) Schematic design. 
Thirteen TE02 aptamers (stem-loops on the left) are placed on the right along a 
linear array of six J1-junctions, and thirteen LD201t aptamers (stem-loops on the 
right) are placed on the left along another linear array of six J1-junctions. The 
parallel lines indicate skipping of two J1-units in between. A 42 bp double-
stranded DNA connects these two parts. b-e) Flow cytometer analysis of cell 
mixtures with this highly polyvalent bispecific aptamers, the linear-branched 
DNA scaffolds only (without the aptamers), DS-DS aptamer, and its polythymine 
control, respectively. 
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2.5 Discussion 
Our demonstration of enhanced cell binding with multivalent aptamers is 
consistent with the findings of several groups.27,28,44 Unlike the linear multivalent 
aptamers described by Mallikaratchy,44 our multivalent aptamers on branched 
DNA nanoscaffolds show significantly enhanced binding avidity over the 
monovalent aptamers (Figure 2.2 and SI, Figure S2.3). The examination of 
different linker flexibili- ties on the binding avidity offers important insight into 
the rational design and optimization of the multivalent aptamer on the DNA 
scaffold structures. 
The multivalent aptamers assembled on 4 × 4 tile-DNA scaffolds are 
relatively more resistant to damaging effects of nucleases in serum compared to 
the monovalent aptamers. This improved stability enables exploiting their use for 
both in-vitro and in-vivo applications. Note that although all DNA strands used 
here were unmodified, the more compact multihelical DNA nanostructures may 
help to protect them from nuclease recognition or attaching. It is also reasonable 
to expect that more nuclease resistance can be achieved by chemical modification 
of the DNA strands or aptamers with 2′-O-Me or 2′-F or by using locked nucleic 
acids, which may further extend their lifespans in vivo.44,45  
Based on these findings, multivalent bispecific aptamer fusions were 
constructed using dimers of five-point-star tiles as scaffolds to induce cell-cell 
interactions. The five-point-star tile retains some flexibility between each arm 
while maintaining its five-point-star shape, 43which promotes a ‘claw’ shape 
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configuration for capturing two cells together (Figure 2.4a,b). In our first design, a 
5-base-long single-stranded region between the two tiles was included, aiming to 
provide some flexibility to adjust the 3D arrangement of the two different cells. 
Cell-cell conjugation was observed using this design with about 22% efficiency. 
The linkage between two tiles only relied on an 8 bp sticky end, which showed 
some degree of dissociation when run on a native polyacrylamide gel at room 
temperature (SI, Figure S2.2). It is speculated that this DS-SS linkage may be too 
weak to keep the two cells together in solution. It is possible that even both 
tetravalent aptamers on the five-point-star tiles could bind to their target cells 
tightly, but they may separate from each other in solution, as a result of the weak 
thermostability of a single 8 bp sticky end. The linkage stability between the tiles 
was improved by incorporating a longer strand into the junction that could 
hybridize with both tiles through DS-DS, which indeed results in a better efficacy 
in promoting cell–cell inter- actions up to ≈37% (Figure 2.6). 
Furthermore, increasing the number of aptamer units per structure creates 
a bispecific linear-branched structure with thirteen-mers of each specificity 
(Figure 2.6a). However, this bispecific structure showed no further improvement 
to cell-cell engagement. Although the distance between each aptamer is similar to 
that on the five-point-star tiles, it is possible that not all of the individual aptamer 
units were properly positioned to interact with their targets on the cell surface, 
especially if the density of these aptamer-binding targets is not sufficiently high. 
This result implicates that, although multivalent aptamers can enhance cell 
targeting, such enhancement is limited by the number of target molecules on the 
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cell surface. Thus, higher numbers of aptamer units do not necessarily confer 
higher binding, and can possibly even lower binding in some cases. A similar 
scenario had also been observed for the Bi-Ab against HLA, a highly abundant 
molecule on cell surface (about 100 000 per T lymphocyte and about 260 000 per 
B lymphocyte),46 which leads to cell–cell interactions with an efficiency of 
37%,14 while Bi-Abs against other surface receptors, e.g., G250 (a relatively low-
expressed renal tumor-associated antigen) could only reach an 11% efficiency. 14 
In our strategy, the target of LD201t aptamer on T cells is L-selectin, 
which has a density in the range of 8000–14 000 per lymphocyte,37,47 and the 
target for TE02 aptamer on B cells is not known yet. By calibrating the response 
of our flow cytometry using a calibrated microbead system (Quantum FITC-5 
MESF Premix, Bangs Laboratories Inc., Fishers, IN), we measured the number of 
TE02 aptamers (monovalent) to be approximately 20 000-25 000 per cell (data 
not shown). It is worthy to note that the densities of target molecules may vary 
upon the activation stage of cells. According to the KD ranges of TE02 and 
LD201t, the concentration of our multivalent bispecific aptamers used already 
reached the saturation level. 
Besides the absolute number of target molecules on cell surfaces, other 
parameters can also influence the cell-cell interactions, including the binding 
affinity of targeting molecules (such as antibodies and aptamers), membrane 
fluidity, and association of the targets with cytoskeleton, as the latter two factors 
can affect the mobility of the targets within the membrane, and therefore their 
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conformation of the engage- ment by target-binding antibody or aptamers. Thus, 
the number of molecules required for such cell-cell engagement may vary from 
cell to cell, and target to target. This can also explain why the configuration of the 
multivalent aptamer may play a critical role in bridging two cells. 
In addition, the functional outcome may also dictate the type of cell-cell 
engagements, ranging from transient synapses to stabilized interactions, which 
could be another variation in the number of molecules required to support such 
interactions. For example, it has been reported that transient synapses between T 
cells and tumor cells by just a few T cell receptors (TCRs) and tumor targets (i.e., 
25–30) was sufficient for an induction of T-cell-mediated killing of tumor cells,48 
and could be redirected by a small amount of bispecific antibodies that bind to 
TCR and tumor targets.49 Thus, with the flexibility of our DNA-scaffolds in 
grafting different numbers and kinds of aptamer units, we can readily modulate 
the avidity and configurations of targeting binding aptamers for appropriate 
cellular synapses as desired. 
Even though the binding affinities of aptamer with their targets are 
intrinsically lower than those of antibodies, we successfully induced cell-cell 
interactions using multivalent, bispecific aptamer fusions, producing comparable 
efficiencies to that achieved by using bispecific antibodies. The level of efficiency 
that we have achieved would be suitable for mimicking biological functions 
carried out between two cells, where moderate and regulated interaction is 
needed. Thus, our results demonstrate the feasibility of multivalent-aptamer on 
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DNA nanoscaffolds in applications where specific cell-cell interactions are 
needed. 
Although our finding points to a new approach to engage cell-cell 
interactions, there are still some challenges in exploring its in-vivo applications, 
such as uncertainties in the stability, size, and pharmacokinetic properties of 
aptamers and DNA scaffolds.36 We may also be limited by the number of 
aptamers currently available. However, with the continuing expansion of aptamer 
pools through SELEX pursued by many research groups, we do expect to have 
sufficient supplies of aptamers for specific cell targeting in the near future. In 
addition, with rapid development in nucleotide modification for increased 
resistance to nuclease, it is possible to create relatively stable bispecific aptamer-
DNA nanoscaffolds for in-vivo applications. Finally, our DNA nanoscaffolds 
could be readily constructed in an optimal range of sizes, unlike small RNAi or 
free aptamers that could be subjected for a rapid removal from the 
body.31Therefore, despite the current limitations in our linking method and the 
availability of aptamer pools, the future potential of this demonstrated method is 
very promising. 
2.6 Conclusion 
Strategies to specifically manipulate cell-cell interactions have attracted 
significant interest over the past few years and are under active investigation to 
elicit biomedical applications. Here, we have constructed multivalent aptamers by 
assembling them onto DNA nanostructures, and utilized this strategy to create 
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multivalent bispecific aptamers for engaging cell-cell interactions. Our findings 
provide a proof-of-concept demonstration of a novel strategy to induce specific 
cell-cell interactions. In this case, cells require no chemical modification and 
maintain their physiological status, making this approach feasible for in-vivo 
applications. Meanwhile, given the robust nature of aptamer selection and 
synthesis, there is no requirement for any animal and/or genetic manipulation. 
Controlled assembly of aptamers onto DNA nanoscaffolds allows us to specify 
the distance, orientation, and conformation of aptamers on DNA nanoscaffolds at 
the nanometer level and facilitates molecular level manipulation to promote cell–
cell interactions. 
As mentioned above, aptamers can be isolated from combinatorial 
libraries against almost any target of interest through SELEX. In theory, any two 
types of cells could be brought together if aptamers specific to each of them could 
be identified. For example, if no appropriate antigen/MHC (major 
histocompatibility complex) were available to unite T cells and B cells in a 
specific disease state, our rationally designed aptamer-DNA nanoscaffolds might 
foster the T-B cell interactions required to generate an effective immune response, 
such as a T cell-dependent B cell response. Also, immune cells could be brought 
into close proximity with tumor cells to trigger their destruction. Since both the 
aptamers and the nanoscaffolds are made of DNA that is biodegradable and 
relatively immunogenetically inert, they should cause little harm to the host. 
Given the relative stability of aptamer-DNA nanoscaffolds demonstrated in our 
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study, we can explore these nanostructures for in-vivo applications and possibly 
develop them into a new line of therapeutic agents. 
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 Chapter 3 
A DNA NANOSTRUCTURE PLATFORM FOR DIRECTED ASSEMBLY OF 
SYNTHETIC VACCINES 
Adapted with permission from Liu, X., Xu Y., Yu T., Clifford C., Yan, H., Liu, 
Y., Chang Y.; A DNA nanostructure platform for directed assembly of synthetic 
vaccines, Nano Letters, 2012, 12(8), 4254-4259. Copyright 2012 American 
Chemical Society. 
Author contributions: Hao Y. and Chang Y. conceived the project, Liu, X., Liu, 
Y., Yan, H., and Chang Y. designed the experiments, Liu X., Xu Y., Yu T., 
Clifford C. performed the experiments, Liu X. wrote the manuscript, Yan H., Liu 
Y., Chang Y. and Nangreave J. edited and proofread the manuscript. 
 
3.1 Abstract 
Safe and effective vaccines offer the best intervention for disease control. 
One strategy to maximize vaccine immunogenicity without compromising safety 
is to rationally design molecular complexes that mimic the natural structure of 
immunogenic microbes but without the disease-causing components. Here we use 
highly programmable DNA nanostructures as platforms to assemble a model 
antigen and CpG adjuvants together into nanoscale complexes with precise 
control of the valency and spatial arrangement of each element. Our results from 
immunized mice show that compared to a mixture of antigen and CpG molecules, 
the assembled antigen-adjuvant-DNA complexes induce strong and long-lasting 
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antibody responses against the antigen without stimulating a reaction to the DNA 
nanostructure itself. This result demonstrates the potential of DNA nanostructures 
to serve as general platforms for the rational design and construction of a variety 
of vaccines. 
3.2 Introduction 
The goal of developing safer and more effective vaccines has been a 
priority since human beings began fighting disease through vaccination over 1000 
years ago1. Many of the vaccines that are currently administered were derived 
from live attenuated organisms, killed whole organisms, or subunit vaccines1,2. 
Although live vaccines have the advantage of inducing a strong immune response, 
there is a risk that the attenuated organism will revert back to a virulent form, 
which is detrimental to the public health. Killed or inactivated whole organisms 
and subunit vaccines do not pose the same serious health risk; however, they tend 
to induce weaker or ineffective immune responses and often require multiple 
doses for enhanced efficacy2. Recombinant DNA technology has facilitated the 
assembly of subunit proteins into virus like particles (VLPs)3,4 that resemble the 
structure of natural viruses but without containing their genetic material, 
representing a major breakthrough in vaccine development. Immunogenic 
epitopes displayed from the VLPs were shown to induce a strong immune 
response and thus, VLPs have been extensively explored as an effective and safe 
platform to assemble the epitopes of interest against many pathogens and tumor 
cells 3,5. However, sometimes, it is challenging to incorporate antigenic epitopes 
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into VLPs at defined positions and configurations because of the inherent 
uncertainties in engineering epitope-VLP fusion proteins4.  
 Alternatively, nanotechnology provides researchers with a robust platform 
for the assembly of subunit vaccines. In particular, biodegradable polymers such 
as poly (D,L-lactide-co-glycolide) (PLGA)2 have been used to encapsulate 
vaccine antigens and adjuvants. These subunit vaccines have been shown to 
increase antigen delivery and antigen presenting cell (APC) targeting, thereby 
enhancing the immunogenicity of the antigen6,7. Today, DNA nanotechnology is 
recognized as a highly programmable and robust way to self-assemble 
heterogeneous nanostructures. A variety of different two- and three- dimensional 
DNA nanostructures8-15 have been constructed and used for precisely organizing 
biochemical molecules16-19 and targeted cellular transport and delivery20-22. 
Gaining control over structural features such as particle size and shape, epitope 
valency, and configuration is highly desirable and long sought after in vaccine 
development and DNA nanostructures present an opportunity to exert such 
control. Several research groups have assembled multiple adjuvant elements on a 
DNA nanostructure and found increased immunostimulation in vitro23,24and ex 
vivo25. Here we provide the first evidence that antigens and adjuvants assembled 
by DNA nanostructures induce strong antibody responses in vivo, highlighting the 
potential of DNA-nanostructures to serve as new platforms for vaccine 
construction.  
We used a tetrahedral DNA nanostructure26-28 as a scaffold to assemble a 
model antigen, streptavidin (STV), and a representative adjuvant, CpG ODN29 
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(mouse-specific ODN-1826), into a synthetic vaccine complex (Figure 1). This 
vaccine complex resembles a natural viral particle in both size and shape27,30, 
where the STV and CpG ODN elements are located at particular positions 
(Figures 3.1 and Figure S3.1). The complex was tested both in vitro and in vivo 
for its immunogenicity, particularly its ability to elicit an antibody response 
against the model antigen, STV.  
 
 
Figure 3.1. Schematic design of the DNA scaffolded adjuvant-antigen vaccine 
complex. The CpG ODN adjuvant molecules (Supplementary information and 
Figure S3.1) are depicted as curved purple ribbons in the model. The model 
antigen (streptavidin) is shown in red and the tetrahedral DNA scaffold is 
represented by green helices. The injected vaccine complexes bind specifically to 
B cells and non-specifically to dendritic cells and macrophages. The complexes 
are internalized by the three types of antigen-presenting cells, disassembled, and 
the individual peptide antigens are subsequently presented to T cells to activate 
antibody production by plasma B cells. 
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3.3 Materials and Methods 
3.3.1 Animals:                     
  Female BALB/c mice were obtained from Charles River Laboratories and 
maintained in a pathogen-free animal facility at the Arizona State University 
Animal Resource Center. All mice were handled in accordance with the Animal 
Welfare Act and Arizona State University Institutional Animal Care and Use 
Committee (IACUC). Before experimental treatment, the mice were randomly 
distributed in cages and allowed to acclimate for at least 1 week before 
vaccination. Each 6-week old mouse was immunized subcutaneously with 10 µg 
streptavidin and/or 3.3 µg CpG ODN or equivalent amounts of CpG DNA 
incorporated into DNA scaffold on days 0 and day 27, and challenged 
intraperitoneally with 10 µg of streptavidin alone on day 51. Blood was 
subsequently collected from cheek veins in accordance with the Arizona State 
University IACUC.  
3.3.2 Bone marrow derived dendritic cells (primary DCs)         
Mice were asphyxiated by CO2 and bone marrow from the leg bone was 
extracted and depleted of red blood cells by an ACT lysis buffer (mix 90 mL of 
0.16 M NH4Cl and 10 mL of 0.17 M Tris (pH 7.65); the pH was then adjusted to 
7.2 with 1 M HCl and sterilized). The washed bone marrow cells were cultured in 
Dulbecco’s modified Eagles medium (DMEM, Sigma) supplemented with 10% 
heat-inactivated FBS, 1% penicillin-streptomycin, 1% glutamine, murine 
granulocyte macrophage colony-stimulating facter (GM- CSF, 10 ng/ml, 
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Prospec), and murine IL-4 (10 ng/ml, Prospec) at 37°C with 5% CO2. After 4 
days of growth, the medium was replaced with fresh DMEM supplemented with 
murine GM-CSF (10 ng/ml) and murine IL-4 (10 ng/ml). Cells were harvested on 
day 7 and seeded at a density of 2.5 × 105 cells/well in U-bottom 96-well plates 
(CellStar) with DMEM supplemented with murine GM-CSF (20 ng/ml) and 
murine IL-4 (20 ng/ml) and held overnight before treatment. 
3.3.3 Flow cytometry              
Cells were collected from a culturing dish or well by pipetting or 
trypsinization, intensively washed with buffer (phosphate-buffered saline, 1% 
BSA, and 0.2% sodium azide), centrifuged at 380 × g for 5 minutes, re-suspended 
in the buffer and analyzed by flow cytometry on a FACSCalibur (BD 
Biosciences). Data was analyzed using CellQuest (BD Biosciences). 
3.3.4 Confocal microscopy               
All fluorescent images were collected by a Plan-Neoflur 40×/1.3 oil DIC 
or Plan-Apochromat 100×/1.4 Oil DIC at a working distance of 0.17 using a Zeiss 
LSM 510 laser scanning microscope (Carl Zeiss, Gottingen, Germany) 
connected to a LSM510 laser module with the following lasers: HeNe488 (for 
both PE fluorescence and green fluorescence from LysoSensor) and HeNe633 
(transmitted light image). The emission filter for PE fluorescence is BP505-530, 
and the emission filter for LysoSensor is BP560-615. Fluorescence was recorded 
as square 8-bit images (1042 × 1042 pixels).  
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3.3.5 Antigen internalization:           
2×105 RAW 264.7 cells were seeded on 24-well plates in 0.5ml DMEM 
medium supplemented with 10% heat-inactivated FBS, 1% penicillin- 
streptomycin, 1% glutamine (A20 cells were seeded in 0.5ml RPMI-1640 
mediumsupplemented with 10% heat-inactivated FBS, 1% penicillin-
streptomycin, 1% glutamine, and 50µM 2-mercaptoethanol) and cultured in 37°C 
cell incubator with 5% CO2 overnight before treatment; the following day various 
combinations of free 2.5 µg PE-STV (BD Pharmingen) or equivalent, 0.825 µg 
CpG, and DNA scaffolded complexes were added to each well for various 
incubation times. The cells were subsequently trypsinized before analyzing by 
FACS Calibur (BD Biosciences, San Diego, CA). For primary DCs, 2.5 × 105 
cells were seeded on flat bottom 96-well plates in 200 µl DMEM supplemented 
with 10% heat-inactivated FBS, 1% penicillin- streptomycin, 1% glutamine, 
murine GM-CSF (20 ng/ml), and murine IL-4 (20 ng/ml) overnight before 
treatment. The primary DC cells were subsequently treated with various 
combinations of 1 µg PE-STV or equivalent and 0.33 µg of CpG or equivalent for 
2 hours. The primay DC cells were then either treated with trypsin or incubated 
with PE-AlexaFluor647 labeled anti-mouse CD11c antibodies; CD11c+ PE+ cells 
were analyzed by FACS Calibur (BD Biosciences, San Diego, CA). 
3.3.6 Lysosomal staining             
After incubating the RAW 264.7 cells with various combinations of PE-
STV and CpG for 1.5 hrs, LysoSensor Green (DND-189, Invitrogen, USA) was 
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added to the growth medium at a final concentration of 1 µM. Cells were 
incubated for an additional 30 min before being washed and examined under 
confocal microscopy. 
3.3.7 Detection of anti-STV IgG by enzyme-linked immunosorbant assay 
(ELISA)  
Maxisorp® flat-bottom 96-well plates (Thermo) were coated with 1µg/ml 
streptavidin (MP) in coating buffer (6.06 g/L Tris-base, 0.2 g/L NaN3, pH 9.5) at 
room temperature and held overnight (Figure 3.2). The next day the plates were 
blocked by blocking buffer (10 g/L BSA, 0.1% NaN3, 0.05% Tween-20 in PBS 
buffer) at 37 °C for 1 hour, followed by the addition of diluted mouse serum to 
each well and incubation for an additional 2 hours at 37 °C. The presence of 
serum antibodies was then verified by adding alkaline phosphatase labeled goat 
anti-mouse IgG (Sigma) and subsequently 4-nitrophenyl phosphate disodium salt 
hexahydrate substrate (Sigma). The OD at 405nm was measured using a 
microreader and the anti-STV IgG level was calculated by fitting the OD405 to a 
standard curve that was generated from a standard anti-STV antibody (GeneTex). 
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Figure 3.2 Schematics of ELISA to detect anti-STV antibodies. 
3.3.8 ELISPOT assay:              
Mice were asphyxiated by CO2 and the spleen was extracted and depleted 
of red blood cells by an ACT lysis buffer. The washed spleen cells were incubated 
with 10µg/ml streptavidin in RPMI-1640 media at 37°C with 5% CO2 for 72 
hours, seeded on opaque MultiScreenHTS 96-well Plates (Millipore) that were 
pre-coated with 5µg/ml the capture antibody, goat anti-mouse IgG (Invitrogen), 
and incubated for another 22 hours. The plates were thoroughly washed and the 
presence of spots was detected by adding alkaline phosphatase labeled 
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streptavidin (Vector Laboratories) followed by the addition of BCIP/NBT 
substrate (Sigma) (Figure 3.3). 
 
Figure 3.3 Schematics of the ELISPOT assay to detect STV-specific antibody 
secreting cells. 
3.3.9 Anti-dsDNA antibody detection                
A dsDNA ELISA kit (Calbiotech) and a microscope based anti-nuclear 
antibody kit (ANA kit, Antibodies Incorporated) was used to evaluate the level of 
anti-dsDNA antibodies present in mouse serum samples 18 days post injection 
(Figure 3.4). Detection was performed following manufactures’ instruction with 
modifications to accommodate measurements in mice. Briefly, the secondary 
antibody in ELISA was replaced with an HRP-conjugated goat anti-mouse 
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antibody, and the secondary antibody in the ANA kit was supplemented with 
alkaline phosphatase conjugated goat anti-mouse IgG. For the ANA kit, the 
mouse serum was diluted 20 times.  
 
Figure 3.4 Schematics to illustrate the experimental concept of anti-dsDNA 
antibody detection kit. Left: the anti-dsDNA ELISA kit, the anti-dsDNA antibody 
could be detected by subsequent addition of certain secondary antibodies, as 
shown in Figure 3.2; Right: the ANA kit, the presence of anti-dsDNA antibody 
could be detected by adding fluorescein-labeled secondary antibody under 
confocal microscope, as mentioned in 3.3.4. 
 
3.3.10 Anti-tetrahedron-shaped DNA antibody detection:          
Maxisorp® flat-bottom 96-well plates (Thermo) were coated with 1µg/ml 
avidin in coating buffer (6.06 g/L Tris-base, 0.2 g/L NaN3, pH 9.5) at room 
temperature and held overnight. The next day the plates were blocked by blocking 
buffer (10 g/L BSA, 0.1% NaN3, 0.05% Tween-20 in PBS buffer) at 37 °C for 1 
hour, followed by the addition of 62.5 nM tetrahedron DNA in TAE/Mg2+ buffer 
and incubation at room temeprarture for 30min. Then diluted mouse serum is 
added to each well and incubate for an additional 1 hours at room temperture. The 
presence of anti-tetrahedron-shaped DNA antibodies was then verified by adding 
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HRP labeled goat anti- mouse antibody and TMB super sensitive one component 
HRP microwell substrate (BioFX). The OD at 650 nm was measured using a 
microreader and the relative OD was calculated by comparing to the OD650 of 
the negative control provided in the dsDNA ELISA kit (Calbiotech). 
3.3.11 Statistical analysis:             
Prism 5.0 software (GraphPad) was used to analyze the antibody response, 
memory B cell response, and to determine the statistical significance of 
differences between groups (we applied a one-tailed unpaired student t test. P 
values less than 0.05 were considered significant). 
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3.4 Results 
3.4.1 Delivery of DNA nanostructure to antigen presenting cells 
Targeted delivery of the antigen to the antigen presenting cells (APC), 
including macrophages, dendritic cells (DCs) and B cells, is a vital first step in 
initiating an effective immune response. Previous studies have shown that the 
size, shape, surface charge, hydrophobicity, hydrophilicity, and receptor 
interactions of an antigen can influence its uptake by APCs30.  After 
internalization, the targets are processed and presented to T cells for T cell 
activation. It has been demonstrated that co-localization of antigens and adjuvants 
within the same APCs can augment antigen presentation and T cell activation6. 
Finally, activated T cells assist in the differentiation of antigen-specific B cells 
and the production of the antibodies that are specific to the target antigen, as 
illustrated in Figure 3.1. Given the recent report that DNA nanostructures increase 
the amount of CpG adjuvant molecules that are internalized by APCs24,25, we 
speculated that DNA nanostructures would also increase the amount of antigen 
taken by APCs, thereby promoting co-delivery of the antigen and CpG to the 
same APC population.   
 To test this hypothesis we loaded fluorescently labeled model antigen, 
phycoerythrin conjugated streptavidin (PE-STV), onto the DNA tetrahedron and 
used flow cytometry to track the internalization of the complex in a mouse 
macrophage-like cell line (RAW 264.7).  
  87 
 
Figure 3.5. Antigen internalization in RAW 264.7 cells and primary DCs. (a) 
Representative flow cytometry result showing the cellular PE fluorescence in 
RAW 264.7 cells after 30 minute incubation with PE-STV and/or DNA scaffolds. 
The red, green, and blue traces correspond to STV, directly linked ODN-STV and 
tetrahedron-STV (Supplementary Information), respectively. (b) Representative 
confocal microscopy images showing internalization of PE-STV in RAW 264.7 
cells. The insets show zoom-in images of representative cells. The cartoons below 
each panel represent STV, directly linked ODN-STV and tetrahedron-STV, 
respectively. (c) Histogram showing time-dependent cellular internalization of 
PE-STV in RAW 264.7 cells. The mean fluorescent intensity of PE is plotted 
against the length of incubation time. Each column represents the average of three 
parallel measurements, and error bars are generated from the standard deviation. 
(d) Histogram showing the cellular internalization of PE-STV in primary DCs 
after 2 hour incubation. Each column represents the average of two parallel 
measurements and error bars are generated from standard error of the mean value. 
The cartoons shown below each panel represent free DNA + STV, directly linked 
ODN-STV and tetrahedron-STV, respectively. 
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As shown in Figures 3.5a and 3.5c, internalization of the tetrahedron-PE-
STV complex occurs quickly (within 15 minutes) in the RAW 264.7 cells. 
Confocal microscope analysis (Supplementary Information) of the sample 
confirmed that the PE fluorescent signal was present inside the cells (Figure 3.5b) 
and that the antigens localized to the lysosomes after incubating for 2hrs (Figure 
3.6). The fluorescent signal in the tetrahedron-PE-STV group continued to 
increase up to 6 hours, while no fluorescent increase was observed in the control 
group treated with only PE-STV (Figure 3.5c). This result indicates that the DNA 
scaffold enhances cellular uptake of the antigen. This finding was further 
substantiated in primary DCs (Figures 3.5d, details in SI), but not in a mouse B 
cell line that lacked the specific antibody required to bind STV (Figure S3.4).  
 
Furthermore, after an incubation time of 5 hrs with FBS at room 
temperature, the tetrahedron scaffold remained stable, as more than to 88.7% of 
the DNA band was still retained (Figure S3.3), which may be sufficient for in vivo 
capture by APCs. Our in vitro study, together with previous reports of DNA 
assemblies facilitating adjuvant uptake10,24,25,31,32, suggest that DNA 
nanostructures can promote delivery of both assembled antigens and adjuvant to 
APCs, which is a prerequisite for induction of an effective immune response.  
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3.4.2 Antibody response in the BALB/c mouse model 
We next compared the immunogenicity of the fully assembled 
tetrahedron-STV-CpG ODN vaccine complexes in inducing anti-STV antibody 
responses in a BALB/c mouse model to those of an unassembled mixture of STV 
and CpG ODN, or STV alone. Specifically, we followed the antibody response in 
three groups injected with different combinations of CpG ODN and STV: 1) STV 
only; 2) free STV mixed with CpG; and 3) tetrahedron- STV-CpG ODN complex 
(Supplementary Information, Figure S3.1). The directly linked STV-CpG 
complex was included as a positive control (Figure S3.6). As outlined in Figure 
3.6a, after two immunizations with the DNA scaffolded vaccine complex 
followed by a challenge of STV protein only, serum was collected from each 
mouse group and the level of anti-STV IgG antibodies was assessed using an 
enzyme-linked immunosorbent assay (ELISA). Over a period of 70 days, we 
found that mice immunized with the fully assembled tetrahedron-STV-CpG ODN 
complex developed a much higher level of anti-STV IgGs than the free 
CpG+STV (Figure 3.3b). This reflects the development of long-term immunity 
against the antigen, presumably due to the persistence of long-lived antibody 
secreting plasma cells and/or generation of STV-specific memory B cells.  
 
 To directly evaluate the long-term immunity induced by various 
immunization regimes, we applied an enzyme-linked immunosorbent spot 
(ELISPOT) assay that allows numeration of STV-specific memory B cells present 
in the spleen cells of immunized mice. Specifically, after in vitro stimulation with 
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STV, memory B cells are converted into antibody-secreting cells (ASCs) which 
are detected by the ELISPOT assay. As shown in Figure 3c, significantly elevated 
levels of specific ASCs were found in mice immunized with the tetrahedron-STV-
CpG ODN complex compared to those immunized with free CpG+STV and STV 
only. Thus, the tetrahedron scaffolded-STV-CpG ODN complexes induce a 
stronger and longer lasting anti-STV antibody response, due in part to the 
generation of STV-specific memory B cells.  
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Figure 3.6. Antibody response in BALB/c mice.  (a) Immunization protocol. (b) 
Anti-STV IgG level after antigen challenge. The average antibody level was 
determined from the results of at least eight mice per group and is plotted here. 
The error bars are generated from the standard deviation. (c) Specific memory B 
cell response in mice assessed by ELISPOT. The average was calculated from 
results of at least eight mice per group and the asterisk indicates a p value of less 
than 0.05 as determined by an unpaired student t test. 
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 Beyond the tetrahedral DNA nanostructure described above, we also 
constructed a branch-shaped structure31-33 for antigen-adjuvant co-assembly 
(Supplementary Information, Figure S3.1). The antigen assembled by this 
branched DNA structure (designated as Branch-CpG, Figure S3.1) induces an 
antibody response at a level intermediate between that of free CpG+STV and the 
tetrahedron-STV-CpG ODN complex (Figure S3.7b). Interestingly, in the in vitro 
experiment antigen internalization for the branch-STV complex is lower than for 
the tetrahedron-STV complex, but higher than for free STV (Figure S3.7a). Taken 
together, the different DNA nanostructures appear to influence both the in vitro 
cellular uptake of the antigen, and the in vivo induction of antigen-specific 
antibody responses. This is likely because of differences in the size, shape or 
stability of the DNA nanostructures which may affect their ability to deliver the 
attached antigen and adjuvant to APCs. While the actual mechanisms still remain 
to be elucidated, the observed correlation between an elevated level of antigen 
internalization and a stronger antibody response may provide us with a screening 
tool to predict or identify the optimal DNA nanostructures for subsequent vaccine 
construction and test in vivo. 
In addition to efficacy, the safety of a vaccine platform is another 
important parameter in vaccine design. Any non-targeted immune responses, 
including those against the platform itself, should be minimized. We should point 
out that the amount of antigen and CpG ODN used in our antigen-adjuvant-DNA 
complex to induce a specific immune response is lower than reported elsewhere34, 
implying the reduced chance of this complex to cause overt non-specific 
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activation often associated with injection of free adjuvant. Furthermore, any 
immune reaction mounted against the double stranded DNA scaffold could result 
in tissue damage and trigger autoimmunity; for example, anti-double stranded 
DNA (anti-dsDNA) antibodies are implicated in the pathogenesis of many 
autoimmune diseases including systemic lupus erythematosus35. We measured the 
level of anti-dsDNA antibodies in the mouse serum 18 days post secondary 
immunization, a time when the anti-STV antibody level was still very high and 
anti-dsDNA antibodies, if present, would be detected with the highest sensitivity. 
Using two independent methods, we observed no detectable level of anti-dsDNA 
antibodies in the tetrahedron-STV-CpG ODN group (Figure 3.7).  
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Figure 3.7. Response against the double-stranded DNA scaffold. (a) Results 
analyzed by anti-dsDNA antibody ELISA kit. Relative OD indicates the ratio 
between the measured OD405 for each sample and that of a standard calibrator 
provided by the manufacture. (b) Confocal microscopy images assessing the anti-
dsDNA antibody by ANA kit. i) and ii) slides incubated with positive and 
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negative control serum provided by manufacture; iii) and iv) slides incubated with 
mouse serum from the Free CpG + STV group; v) and vi) slides incubated with 
mouse serum from Tetrahedron-CpG-STV group. 
 
In addition to evaluating the level of anti-dsDNA antibody production, we 
performed ELISA analysis to determine whether there are antibodies generated 
against the tetrahedron-shaped structure. Similarly, no antibodies were detected in 
the mouse serum 18 days post secondary immunization (Figure S3.8). Taken 
together, these results indicate that the antigen-adjuvant-DNA complex is 
relatively safe and that the response induced by the vaccine complex is specific to 
the antigen and not the DNA platform. 
3.5 Conclusion 
In summary, we demonstrated that a DNA scaffold can be used to 
construct an antigen-adjuvant complex that elicits a strong and specific antibody 
response in vivo, without inducing an undesirable response against the scaffold 
itself. The close proximity of the antigen and adjuvant is critical to enhance the 
immunogenicity of a vaccine; directly linking CpG ODN to an antigen has been 
shown to induce a strong B cell response34 (Figure S3.6), however, such direct 
linkages may be subject to certain limitations when constructing more complex 
vaccines. The ability to construct multivalent and multi-specific antigen-adjuvant 
complexes remains a challenge. Programmable DNA nanostructures provide an 
excellent platform for construction of vaccines with multivalency and three-
dimensional configuration, mimicking VLPs. With well-established protein-DNA 
conjugation techniques, it is now feasible to attach a single antigen or adjuvant on 
a DNA strand. Thus, multivalent and multispecific vaccine complexes can be 
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easily achieved by incorporating multiple antigen- or adjuvant- loaded single 
stranded DNAs into the same structure.  The three dimensional arrangement of 
each of the immunogenic components can be readily controlled through the 
rational design of the scaffold sequences. With the rapid development of protein-
DNA and small molecule-DNA conjugation techniques, it may be possible to 
construct even more complex vaccines in which many different immunogenic 
epitopes, “danger signals” that stimulate immune cells, or various therapeutic 
components such as siRNA10can be assembled on the same DNA scaffold to 
enhance the efficacy of the complex vaccines. Our work demonstrates the 
potential of DNA nanostructures to serve as general platforms for vaccine 
development. 
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 Chapter 4 
DEVELOPMENT OF A DNA-SCAFFOLDED NICOTINE VACCINE 
COMPLEX 
Author contributions: Liu Y.，Chang Y.  and Yan H. conceived the project, Liu, 
X., Yan, H., Liu, Y., and Chang Y. designed the experiments, Liu X., Leal J. 
performed the experiments. 
 
4.1 Abstract 
Tobacco smoking is the most common preventable cause of death, of 
which nicotine (Nic) is the principal psychoactive component responsible for 
tobacco dependence. Although commonly used as medication for smoking 
cessation, nicotine replacement therapy (NRT) is not very effective in clinical 
trials. Alternatively, nicotine vaccine has been explored to reduce tobacco 
dependence, by preventing the nicotine molecules from getting into the brain and 
promoting dopamine release.  
Since nicotine is a small hapten that is not immunogenic per se, the current 
strategies to construct nicotine vaccine mostly rely on coupling nicotine to carrier 
proteins to enhance their immunogenicity. However, such strategies could be 
problematic because of uncertainties in the conjugation of hapten to the protein 
carrier, in terms of hapten density, neighboring distance and configuration. Here, 
we are creating a new type of synthetic nicotine vaccine based on DNA 
  101 
nanostructure as the scaffold, and assembling multiple immunogenic components 
together to enhance the immunogenicity.  
DNA is a type of highly programmable molecules and proven to be an 
ideal building material to construct nano-devices with precise control over 3-D 
configurations. We previously had a proof-of-concept demonstration on the 
feasibility of DNA-scaffolded protein antigen as an effective immunogen. We 
intend to extend this technology to rationally design and assemble DNA-
assembled nicotine-vaccines (DNA-Nic).  Our preliminary data shows that after 
primary immunization, the DNA-Nic vaccine complex could already induce anti-
Nic antibody production in mice. Optimization of this vaccine platform will be 
directed to elicit anti-Nic antibody responses with high affinity and long-term 
antibody production. 
4.2 Introduction 
As the most widely used addictive drug in the world, tobacco leads to 
approximately 444,000 deaths in the United States every year. 
(http://www.drugabuse.gov/publications/research-reports/tobacco-addiction) 
Although 70% of smokers want to stop smoking, the majority (more than 85%) of 
those who try to quit actually end up with failure. Among more than 4,000 
chemicals found in the smoke of tobacco products, nicotine is the primary 
addictive component in the tobacco.1 Even with the commonly used nicotine 
replacement therapy, including the usage of nicotine gum, inhaler, nasal spray and 
transdermal patches, as well as treatment with bupropion which is antidepressant, 
clinical trial studies show only modest improvement is seen on the long-term 
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cessation rate1. Therefore, additional therapies to treat and prevent nicotine 
addiction are needed. 
The addictive effect of nicotine is caused by their stimulating effect of the 
mesolimbic reward system in the brain2. Upon smoking, the nicotine molecules 
can rapidly cross the blood-brain-barrier and enter brain within 10-20 seconds, 
and activate the nicotinic acetylcholine receptors (nAChR) on the ventral 
tegmental area (VTA) neurons2,3, where it subsequently increases extracellular 
dopamine, a neurotransmitter. The increased dopamine level will lead to the 
development of drug addiction. Moreover, the pharmacokinetic properties of 
nicotine also enhance its abuse potential, since smoking leads to a rapid 
distribution of nicotine to the brain, and such acute effect of nicotine decreases 
rapidly, so does the associated feeling of pleasure3. In this case, the smoker has to 
continue dosing to maintain the pleasure effect. 
In the recent years, people started to investigate whether it could help to 
utilize a nicotine vaccine for preventing and treating tobacco addiction4. The anti-
nicotine antibody produced by the stimulation of nicotine vaccine might grab the 
free nicotine molecules in the peripheral blood after they enter the systemic 
circulation, and form a nicotine-antibody complex, which is much bigger in size, 
and therefore prevent the nicotine molecules from entering the brain and diminish 
nicotine’s reinforcing effects5. In this way the addicted individual should no 
longer be motivated to get tobacco. More importantly, since individuals who quit 
smoking actually relapse simply due to smoking as little as one cigarettes or two5, 
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the nicotine vaccine may be more helpful in preventing relapse, as the nicotine 
molecules will be taken by antibodies. 
Promising as it may sound, there are a lot of challenges to construct a 
vaccine against nicotine. Nicotine is a small hapten, with molecular weight of 162 
Daltons6. While the minimum molecular weight for a molecule to elicit a specific 
immune response is 10 kDa4, nicotine per se is not immunogenic. The current 
strategies to construct nicotine vaccine mostly rely on coupling nicotine to carrier 
proteins7,8 or viral-like particles (VLP) 5 to enhance their immunogenicity, and 
those nicotine conjugates have been demonstrate successful in vaccination against 
nicotine. However, many of those studies are facing the unwanted response 
against the carrier protein itself, or side-effect of the complete Freund’s adjuvant 
that was used in combination with the conjugate protein8. Thus there are calls for 
new carrier platforms to construct more specific and effective vaccines of 
nicotine. 
 Alternatively DNA nanostructure could be a good candidate as the 
scaffold to assemble nicotine haptens. As mentioned in Chapter 1, DNA is a 
highly programmable molecule, due to its precise and simple Watson-Cricking 
basepairing principal. There have already been a lot of nano-devices built by 
using DNA molecules as the building material, and researchers have already 
demonstrated the site-specific conjugation of various types of molecules to the 
DNA nano-devices. Moreover, recent research further explored the possibility to 
use DNA nanostructures as delivery platforms in vivo,9,10 and it has already been 
demonstrated that DNA nanostructure could enhance the cellular delivery of a 
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variety of bio-functional molecules, including siRNA9, antigen10 and immune-
adjuvant11,12, in a relatively efficient and safe manner. Such features of DNA 
nanostructure make it an ideal platform for rational vaccine design. 
To rationally design a vaccine platform, the first task is to link the antigen 
molecules on the surface of the delivery platform. For hapten vaccines, the 
antigen, hapten molecules, need to be displayed on surface to induce crosslinking 
of B-cell receptors (BCR), which will subsequently lead to B cell activation and 
antibody production. While polymers like PLGA or liposomes have proven to be 
good delivery cargo for protein antigen13, they might have the intrinsic pitfall to 
serve as a platform of haptens since they tend to encapsulate antigens inside rather 
than exposing them on the surface. But for DNA nanostructure, it is convenient to 
display antigens in a site-specific manner: both the position and the configuration 
of the antigen could be precisely controlled and therefore it allows for the 
construction of multivalent antigens on the surface with optimal spatial resolution, 
which could contribute to the specific B cell activation. Secondly, various types of 
immunogenic molecules need to be put onto a vaccine platform to enhance its 
immunogenicity, especially for hapten antigens.  
In our nicotine vaccine, we explored to bring nicotine (antigen), CpG 
ODN (B cell adjuvant), and T-helper peptide (T-helper epitope14) onto the same 
DNA nanostructure, a 12-arm DNA junction15, as shown in Figure 4.1. This DNA 
structure possesses 12 double stranded DNA arms with different sequences, 
which allows for site-specific conjugation of different molecules. And the length 
of each arm is 24bp (~8 nm), rendering the overall dimension theoretically 
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suitable for delivery to antigen presenting cells as well as to lymph node16. T-
helper peptide was investigated to boost the Th cell function when coadministored 
with the antigen14. Linking those components into close proximity with well-
defined spatial arrangement is expected to guarantee that the antigen and 
adjuvants are delivered to the same APC, which will bring the Th cells to them, 
and thereby activate the antibody production in those nicotine-specific B cells. 
Here in this project, I constructed the vaccine complex and tested its in vitro 
activities as well as antibody responses in a C57BL/6 mouse model. 
 
Figure 4.1 Schematic designs of the 12-arm nicotine vaccine complex. The red 
star represents the nicotine molecule, the purple curve line indicates the CpG 
ODN (mouse-specific ODN-1826), and the green curve composed of continuous 
balls represent the T-helper peptide. 
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4.3 Materials and Methods 
4.3.1 Synthesis of nicotine hapten              
The nicotine hapten (S-form)  is synthesized by Rumit Maini in Dr. Sidney 
Hecht’s group at the Department of Chemistry and Biochemistry, Arizona State 
University. The nicotine haptens are dissolved in sterile dimethyl sulfoxide 
(DMSO, Sigma-Aldrich) at a concentration of 70mM (calculated based on the 
weight of nicotine hapten and its molecular weight of 431 g/mole), and stored as 
aliquots in 1.5ml eppendrof tubes filled with argon gas in the -80°C freezer. 
4.3.2 Conjugation of nicotine hapten to keyhole limpet hemocyanin (KLH) and 
bovine serum albumin (BSA) 
The lyophilized KLH (20 mg, Sigma-Aldrich) powder is reconstituted in 2 
mL deionized water to yield a solution of KLH at 10 mg/mL in a buffer of 31 mM 
sodium phosphate buffer, pH 7.4, containing 0.46 M NaCl, 2% PVP, and 41 mM 
sucrose, and stored as aliquots in the -80°C freezer. For nicotine conjugation, 
300µg KLH is further diluted in 150µL PBS (pH 7.4) or 100mM NaHCO3 buffer 
(pH 8.3) to give a concentration of 2 mg/mL (0.224 µM)8. 700-fold or 7000-fold 
access amount of nicotine hapten is added to the KLH solution in a drop-wise 
manner with each drop of 1 µL and vortexing between each drop. The mixture is 
shaken on a vortexer at 4°C overnight. The next day this reaction mixture is 
purified by running through a NAP-5 desalting column (GE) to remove excess 
nicotine, and the recovered product from the NAP-5 column is used for ELISA 
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analysis and mouse immunization. The conjugation of BSA follows the same 
procedure of KLH conjugation. 
4.3.2 A mine-modified DNA                
All of the amine-modified DNA strands are synthesized by Integrated 
DNA Technology, Inc. (IDT). and shipped as standard desalted product. These 
amine-modified DNA strands are purified by 6% or 8% denaturing 
polyacrylamide gel electrophoresis (PAGE) and dissolved in 100 mM NaHCO3 
buffer (pH 8.3) or in the 100 mM KH2PO4 buffer (pH 7.5) at the final 
concentrations of 200-300µM, which is calculated based on their absorbance 
value at 260 nm and the corresponding extinction coefficients provided by IDT. 
4.3.3 Conjugation of nicotine hapten to the amine-modified DNA               
The purified amine-modified DNA strands are reconstituted in the 100 
mM NaHCO3 buffer (pH 8.3) to give a final concentration of 200-300µM. A total 
amount of 20 nmoles of amine-modified DNA is put in a 1.5 mL tube, and 100-
fold access amount of nicotine hapten is added to the DNA solution in a drop wise 
manner, where 1 µL nicotine hapten is added and followed by vigorous mixing on 
a bench-top vortexer at each step. Then the mixed solution containing amine-
modified DNA and nicotine hapten is gently mixed on a bench-top vortexer 
overnight, after which the total reaction volume is brought up to 1.5 mL and ran 
through a 3kDa Amicon column to get rid of excess amount of nicotine hapten. 
The eluted solution from the Amicon column is then loaded to Agilent 1200 
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HPLC and the nicotine-DNA conjugates are separated from free DNA on a 
reverse phage oligo column with an acetonitrile gradient of 10% to 20% over 20 
minutes. The collected nicotine-DNA conjugates solution is lyophilized and 
reconstituted in 50 µL water and stored at -20°C. The conjugation is confirmed by 
MALDI, as shown in Figure 4.4. 
4.3.4 T-helper peptide  and its conjugation of amine-modified DNA         
The T-helper peptide (N’-aKXVAAWTLKAAaZGGC-C’, where a is D-
alanine; X is L-cyclohexylalanine; Z is aminocaproic acid14) is synthesized by 
United Biosystems, Inc. with a purity of >95%. Upon conjugation, the amine-
modified DNA is dissolved in the 100mM KH2PO4 buffer at the concentration of 
200-300µM. A total amount of 10 nmoles of amine-modified DNA is first mixed 
with 1 mg of sulfo-SMCC and shake at room temperature overnight. The next day 
this reaction mixture is run through a NAP-5 column (GE) to get rid of the excess 
amount of sulfo-SMCC and eluted in 10mM phosphate buffer (pH 7.2). Then 7-
fold access amount of T-helper peptide that is dissolved in 0.1% TFA/10% 
acetonitrile is added to the eluted DNA-SMCC solution and left on a 37°C shaker 
for 24hrs. The access amount of T-helper is removed by running through the 
3kDa Amicon column, and the eluted solution is loaded to Agilent 1200 HPLC 
and the T-helper peptide-DNA conjugates are separated from free DNA on a RP-
oligo column with an acetonitrile gradient of 10% to 25% over 30 mins. The 
collected T-helper-peptide-DNA conjugates solution is lyophilized and 
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reconstituted in 50 µL water and stored at -20°C. The conjugation is confirmed by 
MALDI, as shown in Figure 4.4. 
4.3.5 Assembly of DNA scaffolded nicotine complex          
 All of the strands in the 12-arm junction DNA scaffold is mixed at equal 
molar ratio with a final concentration of 2µM of each strand in the TAE/Mg2+ 
buffer. This strand mixture is then heated up to 95°C for 5 min and slowly cooled 
down to 4°C over two hours. The integrity and stability of the formed 12-arm 
junction structure is confirmed by running a 5% non-denaturing PAGE in the 
TAE/Mg2+ buffer at 20°C and 38°C, as shown in Figure 4.5. 
4.3.6 Animals                      
Female C57BL/6 mice were obtained from Charles River Laboratories and 
maintained in a pathogen-free animal facility at the Arizona State University 
Animal Resource Center. All mice were handled in accordance with the Animal 
Welfare Act and Arizona State University Institutional Animal Care and Use 
Committee (IACUC). Before experimental treatment, the mice were randomly 
distributed in cages and allowed to acclimate for at least 1 week before 
vaccination. Each 10-week old mouse was immunized subcutaneously at the base 
of tail with 6.25 µg KLH-nicotine or equivalent amount of nicotine on DNA 
nanostructure on days 0 and day 25. Blood was subsequently collected from 
cheek veins in accordance with the Arizona State University IACUC.  
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4.3.7 Enzyme-linked immunosorbent assay (ELISA)           
The MaxiSorp® flat-bottom 96-well plate (Theromo) was coated 
overnight with 2µg/ml BSA-conjugated nicotine in the coating buffer (6.06 g/L 
Tris-base, 0.2 g/L NaN3, pH 9.5)  at room temperature. The next day the plates 
was blocked by blocking buffer (10 g/L BSA, 0.1% NaN3, 0.05% Tween-20 in 
PBS buffer) at 37 °C for 1 hour, followed by the addition of diluted mouse serum 
to each well and incubation for an additional 2 hours at 37 °C. The presence of 
serum antibodies was then verified by adding alkaline phosphatase labeled goat 
anti-mouse IgM+IgG (Sigma, 1000-fold dilution) and subsequently 5mg/ml 4-
nitrophenyl phosphate disodium salt hexahydrate substrate (Sigma). The OD at 
405nm was measured using a microreader and the anti-nicotine Ig titer was 
calculated as the dilution fold when the OD405 reading is equal to that of the 
negative control well, in no mouse serum but only secondary antibody and 
substrates were added.  
 4.3.8 Competitive ELISA 
The experimental procedure is similar to the conventional ELISA. Instead 
of adding different serum to the coated antigen, a fixed amount of standard anti-
nicotine antibody is mixed with different concentrations of inhibitor (also referred 
as competitor, see green balls in Figure 4.1) that could bind to the antibody as 
well. This mixture is incubated with the coated antigen, BSA-nicotine, on the 96-
well plate, and the extent of competition is then detected by adding the same 
amount of secondary antibody and subsequent substrate to each well. More 
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inhibitor or inhibitors with a higher binding affinity to the primary antibody will 
result in a fainter color of the final product, as shown in Figure 4.2. 
 
Figure 4.2 Competitive ELISA. The inhibitor (green ball) may bind to the primary 
antibody (black), therefore inhibit the binding between the primary antibody and 
coated antigen (grey ball), and result in less amount of secondary antibody (blue) 
that subsequently bind to the primary antibody on the plate, producing less 
amount of final color generating product when the substrate is added. 
4.3.9 Cell culture 
All of the cells were cultured in Dulbecco’s modified Eagles medium 
(DMEM, Sigma) supplemented with 10% heat-inactivated FBS, 1% penicillin-
streptomycin, at 37°C with 5% CO2. 
4.3.10 Cellular internalization of the 12-arm DNA junction        
2×105 RAW 264.7 cells (mouse macrophage-like cell line) were seeded on 
24-well plates in 0.5ml DMEM (Dulbecco’s Modified Eagle medium) medium 
supplemented with 10% heat-inactivated FBS, 1% penicillin-streptomycin, and 
cultured in 37°C cell incubator with 5% CO2 overnight before treatment. The 
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following day 200 nM AlexaFluor488 (AF488)-labeled DNA nanostructures or 
single-stranded DNA were added to each well for various incubation times. The 
cells were washed by PBS buffer and trypsinized for 5 min at 37°C before being 
collected. Then the cells were treated with DNase (Sigma-Aldrich) in 37°C water 
bath for 10 min to remove any DNA that might attach to the cell surface 
nonspecifically and washed with PBS before being analyzed by FACS Calibur 
(BD Biosciences, San Diego, CA). For peritoneal cavity cells, 100 µL 1.34 µM of 
FRET pair labeled 12-arm DNA junction was injected intraperitoneally to the 
mice and the intraperitoneal fluid was recovered by flushing the peritoneal cavity 
with 3 mL ice-cold PBS after 1.5 hrs. Then the recovered peritoneal cavity cells 
are washed with PBS and incubated with DNase in a 37°C water bath before 
analyzing by FACS.     
4.3.11 Flow cytometry              
Cells were collected from a culturing dish or well by pipetting or 
trypsinization, intensively washed with buffer (phosphate-buffered saline, 1% 
BSA, and 0.2% sodium azide), centrifuged at 380 × g for 5 minutes, re-suspended 
in the buffer and analyzed by flow cytometry on a FACSCalibur (BD 
Biosciences). Data was analyzed using CellQuest (BD Biosciences). 
  113 
4.4 Results 
4.4.1 Nicotine-protein conjugation  
KLH (keyhole limpet hemocyanin) is a large protein consisting of subunits 
with molecular weight of 400kDa and it can exist in different aggregation states 
depending on the pH and divalent ion concentrations, with the molecular weight 
of 4-8 × 106 Dalton (Sigma-Aldrich®). There are many lysine residues on the 
surface of KLH protein (normally 300-700 accessible for conjugation, according 
to Pierce), which render it a perfect carrier for hapten conjugation through 
different heterogeneous crosslinkers. To maximize the conjugation efficiency, we 
compared different reaction buffer conditions and different conjugation ratios, and 
got the optimal reaction condition to conjugate nicotine hapten to KLH in a 
saturated level. As shown in Figure 4.3, the 100 mM NaHCO3 buffer is shown to 
be a better reaction buffer than the PBS buffer, and 700-fold access amount of 
nicotine hapten in the 100mM NaHCO3 already saturates the reaction, whereas 
7000-fold access amount of nicotine hapten did not further increase the coupling 
efficiency. Therefore we picked up nicotine-KLH conjugates from those two 
NaHCO3 groups for mouse experiments. 
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Figure 4.3 Competitive ELISA to compare the nicotine-coupling efficiency at 
different reaction conditions. All the OD readings from each group are normalized 
by comparing to the standard control wells where no competitor is added. 
Decrease in the percentage of binding indicates inhibition of binding between the 
anti-nicotine antibody and the protein-nicotine conjugates competitor. Better 
inhibition of binding indicates more numbers of nicotine molecules are 
conjugated to the corresponding protein. Increasing the reaction ratio of nicotine 
to protein enhanced the conjugation efficiency in PBS, but not in sodium 
bicarbonate buffer.  
  115 
4.4.2 Nicotine-DNA conjugation and T-helper peptide-DNA conjugation 
Conjugation of the nicotine to the amine-modified DNA is confirmed by 
MALDI-TOF in combination with HPLC traces, as shown in Figure 4.4 a-c. The 
molecular difference before and after conjugation should be 315 Dalton, but for 
two of all four nicotine-DNA strands, the measured molecular difference is less 
than this value. It could be possibly because of the accuracy of the MALDI-TOF 
instrument used. Therefore we provided the HPLC trace to confirm the 
conjugation. In the HPLC trace, the first peak indicates the free DNA strand that 
was not conjugated with nicotine, whereas the second peak bearing higher 
hydrophobicity shows the nicotine-DNA conjugates.  
The conjugation of T-helper peptide to DNA is shown in Figure 4.4 d-f, 
and the measured molecular differences is as expected. 
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Figure 4.4 HPLC traces and MALTI-TOF results to confirm the conjugation of 
nicotine or T-helper peptides on the DNA strands. Strands with the names of 12-
2, 12-5, 12-8, 12-11 are conjugated with nicotine and strands with the names of 
12-3, 12-6, 12-9, 12-11 are conjugated with T-helper peptides. a) HPLC traces of 
representative nicotine conjugation; b) MALDI-TOF on the DNA strands before 
nicotine conjugation; c) MALDI-TOF on DNA strands after nicotine conjugation; 
a) HPLC traces of representative T-helper peptide conjugation; b) MALDI-TOF 
on the DNA strands before peptide conjugation; c) MALDI-TOF on DNA strands 
after peptide conjugation.  
The formation of 12-arm DNA junction with nicotine, CpG ODN and T-
helper peptide is confirmed by 5% non-denaturing PAGE gel (Figure 4.5). The 
whole structure remained stable at both lower temperature (20°C) and higher 
temperature (38ºC), implying it has enough thermal stability for in vivo injection. 
 
  117 
Figure 4.5 Non-denaturing 5% PAGE gels confirm the correct assembly of the 
total12-arm DNA vaccine complex (including nicotine, CpG ODN and T-helper 
peptide) and its thermal stability around physiological temperature. The yield of 
the expected whole vaccine complex is above 85% as measured by the software 
ImageJ (NIH). 
 
4.4.3 Competitive ELISA confirms the nicotine molecules are displayed on the 
surface of 12-arm DNA junction 
For a vaccine to induce T-cell dependent antibody production in the B 
cells, it is important that the antigen molecules could be recognized by the 
specific B cell, and ideally the antigen molecules should be displayed with certain 
local density to induce crosslinking of B-cell receptors (BCR) and therefore 
subsequent activation of this antigen-specific B cells. Thus it is crucial to confirm 
that our nicotine molecules are displayed on the surface the DNA nanostructure 
with certain multivalency.  
There has not been any report on the three-dimensional model of the 12-
arm DNA junction, however, by using the software CadNano and online tool 
CanDo, we modeled the three-dimensional structure of the 12-arm DNA junction. 
As shown in Movie 4.1 and Figure 4.6, each arm of the 12-arm junction is 
pointing out. Since we placed the nicotine molecules at the end of four arms, the 
most flexible region in this 12-arm DNA junction structure, it is expected that the 
nicotine molecules should be displayed on the surface of this 12-arm junction. 
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Figure 4.6 Three-dimensional model predicted by CanDo (http://cando-dna-
origami.org/) and caDNAno (http://cadnano.org/). The predicted shape with 
flexibility is illustrated as a heat-map, where red color indicates high flexibility 
and blue color indicates low flexibility. 
a) Planar design of 12-arm DNA junction as drawn in the software caDNAno and 
corresponding cylinder model by CanDo. Each cylinder represents a DNA 
double-helice. b) Computer predicted fluctuation map of the 12-arm DNA 
junction visualized from the direction of x-axis in a). c) Computer predicted 
fluctuation map of the 12-arm DNA junction visualized from the direction of y-
axis in a). d) Computer predicted fluctuation map of the 12-arm DNA junction 
visualized from the direction of z-axis in a). 
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Then we measured the particle size of the assembled vaccine complexby 
dynamic light scattering (DLS). The DLS result shows that the average radius of 
our vaccine particle is 7.185±0.520 nm (Supplemental information, Figure S4.2, 
DLS measurement is performed by Xixi Wei in Dr. Yan Liu’s group at 
Department of Chemistry and Biochemistry, Arizona State University). If it is 
simplified as a sphere structure, our vaccine complex has a radius of 24 bp double 
stranded DNA, which is calculated to be around 7-8 nm. And the DLS data is 
consistent with this simplification, indicating that the fully assembled vaccine 
complex might represent a sphere-like structure, therefore exposing the antigen, 
nicotine molecules, outside. 
To further confirm this configuration, we carried out competitive ELISA 
experiment for demonstration (see Figure 4.1 for experimental details). The 
inhibitor could only compete or inhibit the binding between anti-nicotine antibody 
and the plate-coated nicotine when the inhibitor contains nicotine, and at the same 
time those nicotine molecules are displayed on the surface, which would make 
them accessible to the anti-nicotine antibodies. Here we tested different set of 
competitor with competitive ELISA, as shown in Figure 4.7. 
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Figure 4.7 Competitive ELISA to compare different DNA-scaffolded nicotine 
complexes. All of the OD readings from each group are normalized to the 
standard control wells where no competitor is added. The BSA-nicotine group is 
included as a positive control for competition since there could be 10-20 nicotine 
molecules conjugated on one BSA molecule, whereas the group of 12-arm peptide 
is included as a negative control since there are no nicotine molecules on it. 
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              In this figure, it is shown that the 12-arm junction bearing four nicotine 
molecules competes the best among all the 12-arm junctions tested, whereas the 
one with two nicotine molecules competes second best, the single-stranded DNA-
nicotine competes similarly as the free nicotine hapten, and the 12-arm junction 
without any nicotine does not compete at all. Such result shows that there were 
indeed four nicotine molecules conjugated to each of the 12-arm junction 
structure, which further confirmed our conclusions in 4.4.1, and each of those 
nicotine molecules are actually displayed on the surface of this 12-arm DNA 
junction, which confirms our prediction in Figure 4.5. It is also worthy to mention 
that the 12-arm DNA junction bearing all four nicotine molecules competes 
almost as well as the BSA-nicotine conjugate, the positive competing control, 
which has been shown to present 10-20 nicotine molecules in total. This indicates 
that the three-dimensional spatial arrangement of nicotine molecules on our 12-
arm DNA junction structure might in an optimal configuration for its binding to 
the anti-nicotine antibodies. Such conjecture makes sense, as if the whole 
structure is simplified as a sphere shape, the distance between the ends of two 
adjacent arms is around 5.5 nm, which fits in the distance between the two ends of 
the Fab fragment in the same antibody molecule17. Moreover, it also demonstrates 
that the conjugation of T-helper peptides and the linkage of CpG ODN onto the 
12-arm junction structure do not interfere with the binding between the antigen 
nicotine and its antibodies. Taken together, our 12-arm DNA junction present the 
antigen nicotine molecules on its surface in a multivalent manner, and such three-
dimensional arrangement of the nicotine molecules render it possible to interact 
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with the B cell receptor (BCR) on the nicotine-specific B cells, which will be 
promising to induce the production of anti-nicotine antibodies. 
4.4.4 Internalization of DNA scaffold in vitro 
As mentioned in Chapter 3, the antigen internalization is an initial and 
crucial step in the antibody producing pathway10. Moreover, since in Chapter 3, 
we observed that there might be correlation between the in vitro antigen 
internalization efficiency and the in vivo antibody production level10, it is 
necessary to measure whether this 12-arm DNA junction could enhance the in 
vitro antigen internalization to APC, and how strong it could enhance this 
internalization. However, different from the streptavidin antigen used in Chapter 
3, we are using a small molecule here, rendering it difficult to directly label the 
antigen with tracking signal such as fluorophores. Alternatively, we labeled the 
DNA AlexaFluor 488 dye scaffold at the similar position where the nicotine 
hapten was conjugated, and tracked its signal inside the cells. Specifically we 
compared the internalization efficiency of different DNA nanostructures, 
including single-stranded DNA, four-arm DNA junction, eight-arm DNA 
junction, and twelve-arm DNA junction, where the arm of each DNA junction is 
of same length. 
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Figure 4.8 In vitro internalization of AlexaFluor488-labeled DNA nanostructures. 
RAW 264.7 cells seeded on 24-well plate were treated individually with 
AlexaFluor488-labeled single-stranded DNA (ssDNA), AlexaFluor488-labeled 
four-arm DNA junction (4-arm), AlexaFluor488-labeled eight-arm DNA junction 
(8-arm), and AlexaFluor488-labeled twelve-arm DNA junction (12-arm) for 2hrs 
and analyzed for internalization of the AlexaFluor488 signal. Mean fluorescent 
intensity (M. F. I.) of AlexaFluor488 is read from the CellQuest software, and the 
error bars are generated from two parallel wells of cells. 
As shown in this figure, 8-arm DNA junction significantly enhanced the 
cellular internalization over the 4-arm DNA junction. This could be due to the 
change in structure pack density, charge, or surface area. However, increasing the 
arm number from eight to twelve did not further enhance the cellular 
internalization, which could be due to the fact that the 8-arm junction might be 
structurally more similar to the 12-arm junction than to the 4-arm junction. 
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Since the DNA nanostructures tested could enhance the cellular delivery 
of small molecules, our next question is how stable they are intracellularly and 
extracellularly.  To address such questions, one FRET pair is introduced to the 
DNA nanostructure to monitor its stability, since the 12-arm junction structure is 
geometrically symmetric and stability of one arm would indicate the stability of 
every other arms. Briefly, two dye molecules, AlexaFluor488 (donor) and 
TAMRA (acceptor), are introduced to the 5’ end of strand 12-2 and the 3’ end of 
strand 12-1, respectively. Thus the distance between the donor and acceptor is 
approximately 2nm, which is good for FRET. The FACS instrument used in this 
experiment only has one laser power of 488 nm, which could not excite the 
TAMRA molecule (excitation peak 532 nm) when there is no FRET effect. 
Therefore we would expect to collect the emission signal of the acceptor upon 
excitation of the donor only when the DNA structure is intact, while decreased or 
diminished emission signal from the acceptor will indicate the degradation of the 
12-arm junction DNA structure. To further test whether the degradation happened 
inside cell or outside cell in the culture medium, a secondary incubation is added, 
where the same cell-culture medium containing FRET-labeled 12-arm DNA 
structures is transferred to a non-treated well of cell at each time point, and 
continued to incubate with those non-treated cells for an additional hour. As 
shown here in figure 4.9, the percentage of AF488+/TAMRA+ cells increased 
during the period of time from 1hr to 6hr, while decreased by 24hr. At the same 
time the signal ratio of TAMRA over AF488 in the secondary incubation, which 
indicates the structure integrity, maintained at a stable high level from the 1hr 
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group to 6hr group, but decreased drastically in the 24hr group. It indicates that 
our DNA structure maintained its integrity both inside cell and in the culture 
medium for at least 6hrs, and by 24hr there are still a certain amount of intact 
DNA structures inside the cells. Those above observations provide the 
information of DNA structure stability, as well as information of time scale to our 
in vivo internalization experiment. 
 
above observations provide the information of DNA structure stability, as well as 
information of time scale to our in vivo internalization experiment. 
 
 
Figure 4.9 Internalization of FRET-labeled 12-arm DNA junction in RAW 264.7 cells. a) 
The FRET-labeled DNA nanostructures are incubated with cells for 3hr, 6hr, 11hr, and 
24hr respectively. FL-1 channel indicates the fluorescent signal of AF488 and FL-2 
channel indicates the fluorescent signal of TAMRA. b) The ratio of TAMRA/AF488 
(mean fluorescent intensity) are normalized to that at 1hr incubation and plotted as 
columns. Upper panel indicates the ratio of primary incubation and the lower panel 
indicates that after medium transfer. 
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6hr, 11hr, and 24hr respectively. FL-1 channel indicates the fluorescent signal of 
AF488 and FL-2 channel indicates the fluorescent signal of TAMRA. b) The ratio 
of TAMRA/AF488 (mean fluorescent intensity) are normalized to that at 1hr 
incubation and plotted as columns. Upper panel indicates the ratio of primary 
incubation and the lower panel indicates that after medium transfer. 
4. 4. 5 Internalization of 12-arm DNA nanostructure in vivo 
The environment of blood circulation in vivo is much complicated than 
the in vitro cell culture environment, including the circulating nucleases, therefore 
the internalization and stability of the DNA nanostructures in vivo might be 
different from that in vitro. Here we utilized the FRET-labeled 12-arm DNA 
junction to monitor its internalization inside the peritoneal cavity. The peritoneal 
cavity refers to the space between the parietal peritoneum and visceral peritoneum, 
and contains a lot of blood and lymph vessels and nerves. Intraperitoneal injection 
is used when a large amount of fluid is injected or when administration of 
systemic drug is needed. Peritoneal fluid cells (PFC) contains all forms of 
nucleated cells found in the circulating blood, including histiocytes or 
macrophages, mast cells, and a few desquamated mesothelial cells, and 
proportions of those cell types may change when there is stimulation or irritation. 
Moreover, it has been reported that upon bacterial infection, there would be a lot 
of neutrophil granulocytes migrating into the peritoneal fluid for depleting the 
invasive bacteria as well as functioning as unprofessional antigen presenting cells 
for antigen presentation. 
In this experiment, we harvested the PFC 1.5 hrs after the intraperitoneal 
injection of FRET-labeled 12-arm DNA junction and analyzed the FRET signal 
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inside this cell population. As shown in the forward/side scatter plot, there are 
mainly three types of cells, corresponding to lymphocytes, macrophage 
(monocytes), and neutrophils (granulocytes). Of all those cells, the population of 
neutrophils (granulocytes) is the most active cell population that takes up the 
DNA particle rapidly, where as the lymphocyte is the least active population and 
the macrophage (monocyte) is the medium population in taking up DNA 
nanostructures. This result is not surprising considering the intrinsic active 
phagocytosis activity of neutrophils and the role of macrophages as the 
professional antigen presenting cells. And the in vivo internalization result, in 
combination with the in vitro internalization results, is promising as the antigen 
internalization is a prerequisite and indicator of potential antibody production in 
the animal model. 
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Figure 4.10 In vivo internalization of 12-arm DNA junction. a) Representative 
forward and side scatter of peritoneal fluid cells. The cells are gated as different 
populations, with each representing different types of cells. G represents for 
granulocyte (mostly neutrophil), L represents fro lymphocytes, and M represents 
for monocytes (mostly macrophages). b) Double staining pattern of lymphocytes 
from the mouse injected with FRET pair-labeled 12-arm DNA junction structure. 
c) Double staining pattern of monocytes from the mouse injected with FRET pair-
labeled 12-arm DNA junction structure. d) Double staining pattern of 
granulocytes from the mouse injected with FRET pair-labeled 12-arm DNA 
junction structure. 
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4. 4. 6 Anti-nicotine antibody responses in vivo 
We next explored the immunogenicity of out assembled DNA-nicotine-
peptide-CpG vaccine complex in vivo. The KLH-nicotine, which is physically 
mixed with CpG ODN and Freud’s incomplete adjuvant, serves as a positive 
control. And the amount of DNA vaccine complex injected in each mouse was 
carefully adjusted to match the amount of nicotine molecules on KLH. 
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Figure 4.11 Anti-nicotine response in C57BL/6 mouse. a) antibody response two 
weeks post primary immunization; b) antibody response 10 days post secondary 
immunization; c) antibody response 9 days post secondary immunization. 
Antibody titer is defined as the dilution fold when the OD405 reading drop to the 
background (the well added with everything except for the serum) level. 
 
As shown in Figure 4.11, the DNA scaffolded nicotine vaccine complex 
induced a moderate antibody response in the mouse, a level significantly higher 
than the background (negative control of PBS buffer), but lower than the positive 
control of the KLH-nicotine complex. This result is encouraging since it 
demonstrates that the DNA scaffolded nictotine vaccine complex does induce 
antibody response against the nicotine molecules. 
4.5 Discussions 
Our experiments showed that the 12-arm DNA junction structure could 
facilitate the delivery of antigen molecules into APC both in vitro and in vivo, and 
the fully assembled vaccine complex composing the antigen and different 
adjuvants could indeed induce specific antibody response against the nicotine 
molecules.  
On the other hand, there are still spaces for improving the efficacy of the 
DNA scaffolded vaccine complex. One possible modification is to change the 
antigen density and spatial arrangement on the DNA scaffold. KLH is a huge 
protein containing hundreds of amine groups for nicotine conjugation, and 
therefore the local concentration of nicotine in very high. This high local density 
of nicotine provides multiple units for BCR crosslinking and could possibly 
benefit the B cell activation. To match this high local nicotine density, one 
improvement of the DNA scaffolded vaccine is to change the DNA scaffold into a 
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more compact structure, which would allow for assembling more antigen 
molecules on the surface. Another possible modification is to increase the T-
helper peptide number or change into other T-helper peptides that are more 
efficient in activating T helper cells. Once internalized and degraded, KLH could 
possibly provide thousands of peptide fragments that might possibly serve to 
engage T helper cells, while in our current vaccine complex, only four T-helper 
peptides are conjugated on each vaccine molecule. By modifying the current 
DNA scaffold, it is very likely that the antibody level could be further enhanced. 
Moreover, the therapeutic efficiency of the nicotine vaccine is related to the 
antibody titer in long-term immune response as well as the binding affinity of 
anti-nicotine antibody to nicotine. Potentially such binding affinity should be 
tested and the long term immune response by those vaccines should be evaluated. 
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Chapter 5 PERSPECTIVES OF BIOLOGICAL APPLICATIONS BY DNA 
NANOSTRUCTURE 
The field of DNA nanotechnology has been growing rapidly over the past 
decade, and more and more attention has been drawn to utilizing the DNA 
nanostructures for biomedical applications. My research projects illustrate the 
potential of employing DNA platfroms fot immunological applications. Although 
still preliminary, those explorations indicate that DNA nanotechnology could be a 
well-defined and highly programmable technique for disease treatment and 
prevention. Promising as it shows, there are various challenges as well as 
opportunities for the nanomedical application of DNA nanostructures. 
Seeking for effective and safe strategies to prevent infectious diseases has 
been a big challenge drawing intensive attentions in the human biomedical 
history. Traditional vaccinations have successfully prevented or even eliminated 
the occurrence of many diseases that were thought to be severe or even life-
threatening. Howver, on one side the evolve of the pathogens render the existing 
vaccines less effective, and on the other side the mechanism of more diseases are 
being identified calling for new prevention strategies for them. Therefore, 
“designing” new vaccines in a rational way is in need. My research project 
demonstrated a new synthetic vaccine design strategy by using DNA 
nanostructure as the platform to assemble multiple immunogenic molecules, and 
the research on developing a DNA-scaffolded nicotine showed that anti-nicotine 
antibody was produced in vivo. Although the antibody level is moderate, and 
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lower than that produced by the conventional vaccination strategy, the presence of 
nicotine antibodies is already a remarkable success, considering the fact that an 
immunologically inert DNA scaffold is used in this vaccine. For future 
optimization of the DNA-scaffolded hapten vaccine, several parameters could be 
considered. One parameter is the density of antigens. B cell is activated through 
the crosslinking of BCR, and multiple hapten molecules on the same entity 
provide a high local concentration of those haptens, thereby affording higher 
possibility of the BCR crosslinking. Compared to the conventional protein carrier, 
the number of haptens on each DNA scaffold is much lower than that on each 
protein, suggesting the local density of hapten might play a role in eliciting high 
level of antibody response. Another consideration to evaluate the efficacy of 
DNA- scaffolded nicotine vaccine is to test the binding affinity of the produced 
anti-nicotine antibody, since higher affinity may lead to tighter binding to free 
nicotines and subsequent better capacity in preventing the free nicotines to enter 
the brain. If the antibody level could be further increased and the binding affinity 
are evaluated strong, the DNA-scaffolded nicotine vaccine complex could 
potentially generate excellent clinical consequence and may be commercialized to 
help more and more people quit or control smoking as they desire, and thus 
creating great social benefits. 
Moreover, such vaccine design strategy might be expanded to the 
prevention of various life-threatening diseases such as cancers and HIV. As the 
current cancer vaccines are developed for preventing cancer in the healthy people, 
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as well as treating the pre- existing cancers in patients, improvement in cancer 
vaccine design would benefit the healthy population as well as the patients. 
Furthermore, as mentioned in Chapter 1, DNA nanostructures can be 
constructed and functionalized as individual “module”, and there is research on 
multiplexing different modules. One of the future trends for DNA nanotechnology 
is to take advantage of its modularity and create multi-functional nanodevices. In 
that case, the functions of disease diagnosis, treatment and prevention could be 
incorporated into the same scaffold complex. For example, a NK cell-tumor cell 
bispecific targeting module could be linked with a tumor vaccine, and thus both 
cytotoxicity and vaccination could be achieved with this nanodevice. 
In summary, there have been intensive investigations on the biological 
applications of DNA nanotechnology, with emphasis on aspects such as disease 
diagnosis, treatment and prevention. Although still preliminary so far, it is 
developing and expanding rapidly, and there is tremendous space to explore more 
and more experimental and clinical studies on this topic. And we could expect a 
brand new nanomedical world with smart DNA devices carrying various 
functions to revolutionize the way of diagnosis and therapeutics. 
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APPENDIX A 
SUPPLEMENTAL INFORMATION FOR CHAPTER 2 
(TARGETED CELL-CELL INTERACTION BY DNA NANOSCAFFOLD-
TEMPLATED MULTIVALENT BISPECIFIC APTAMERS) 
  159 
  160 
  161 
  162 
  163  
  164 
Supplemental Figure S2.1 Structure of the DNA scaffolds used to create the 
multivalent aptamers or bi-specific aptamer fusions. a. Rigid TE02 homodimer; b. 
Flexible TE02 homodimer; c. Rigid TE02 homo-trimer; d. Flexible TE02 homo-
trimer; e. Rigid TE02 homo-tetramer; f. TE02/LD201t1 hetero-octamer; g. 
TE02/LD201t hetero-26 mer. The green lines indicate the TE02 monomers and 
the blue lines indicate the LD201t1 monomer. 
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Supplemental Figure S2.2 Specific binding of each individual monovalent 
aptamers to their target cells. a.Flow cytometry result when FITC-TE02 (red 
trace) and FITC-LD201t1 (green trace) are incubated with Ramos cells. b. Flow 
cytometry result when FITC-TE02 (green trace) and FITC-LD201t1 (red trace) 
are incubated with Jurkat cells. The black trace corresponds to the negative 
control with buffer only. 
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Supplemental Figure S2.3 Specific binding of each individual monovalent 
aptamers to their target cells. a.Flow cytometry result when FITC-TE02 (red 
trace) and FITC-LD201t1 (green trace) are incubated with Ramos cells. b. Flow 
cytometry result when FITC-TE02 (green trace) and FITC-LD201t1 (red trace) 
are incubated with Jurkat cells. The black trace corresponds to the negative 
control with buffer only. 
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Supplemental Figure S2.4 Nuclease-stability of DS-DS and DS-SS aptamer 
constructs upon their incubation with a cell line that does not bind to either of the 
aptamers. 120 nM of DS-DS or DS-SS aptamers in 50µL binding buffer were 
incubated with 5X105 cells (as depicted by +) on ice for 0.5, 1, and 2 hours, and 
separated on 3.5% native PAGE. Black arrow indicates the bands for the DS-SS 
aptamer construct and red arrow indicates the bands for the DS-DS aptamer 
construct. The gel is stained by ethedium bromide. The middle lane is a 100 bp 
ladder. No significant dissociation of the DNA nanostructure was observed in 
both cases. The fast migrating band that appear in the positive lanes does not 
show increase intensity with time, which may come from the cells. 
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Supplemental Table S2.1 Analysis of cell-cell interactions by multivalent bi-
specific aptamers.  
Construct Linkage efficiency (%) a] 
DS-DS aptamer 34.0±3.8 
DS-DS control 4.1±0.7 
DS-SS aptamer 22.9±1.8 
DS-SS control 3.0±0.9 
a] Experiments were performed for at least three times and linkage efficiency is 
expressed as (average ± standard deviation)%. 
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Oligonucleotide sequences  
TE02: 
5'TAGGCAGTGGTTTGACGTCCGCATGTTGGGAATAGCCACGCCT3’ 
LD201t1: 
5'TAGCCAAGGTAACCAGTACAAGGTGCTAAACGTAATGGCTTCGGCTT
AC3' 
Bivalent TE02: 
Duo-1: 
5'TAGGCAGTGGTTTGACGTCCGCATGTTGGGAATAGCCACGCCTATAG
GAGGTG CGACGAGGAA3’ 
 
Duo-2: 
5'CCTTGATGTACTCTCATTCGTAGGCAGTGGTTTGACGTCCGCATGTTG
GGAATAGCCACGCCT 
 
Duo-3: 5'CGAATGAGAGTCAAGGTTCCTCGTCGCACCTCCTAT 
Flexible duo-3: 
5'CGAATGAGAGTCAAGGTTTTTTTCCTCGTCGCACCTCCTAT 
Trivalent TE02: 
Rigid Tri-1: 
5’AGGTGACACACCGATGACGCTAGGCAGTGGTTTGACGTCCGCATGTT
GGGAATAGCCACGCCT3’ 
Rigid Tri-2: 
5’GCGTCATCGGACGATCAGAGTAGGCAGTGGTTTGACGTCCGCATGTT
GGGAATAGCCACGCCT3’ 
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Rigid Tri-3: 
5’CTGTAAATCCTGTGTCACCTTAGGCAGTGGTTTGACGTCCGCATGTT
GGGAATAGCCACGCCT3’ 
Tri-4: 
5’CTCTGATCGTGGATTTACAG3’ 
Flexible Tri-1: 
5’AGGTGACACACCGATGACGCTTTTTTTTTTTAGGCAGTGGTTTGACG
TCCGCATGTTGGGAATAGCCACGCCT3’ 
Flexible Tri-2: 
5’GCGTCATCGGACGATCAGAGTTTTTTTTTTTAGGCAGTGGTTTGACGT
CCGCATGTTGGGAATAGCCACGCCT3’ 
Flexible Tri-3: 
5’CTGTAAATCCTGTGTCACCTTTTTTTTTTTTAGGCAGTGGTTTGACGT
CCGCATGTTGGGAATAGCCACGCCT3’ 
Tetravalent TE02: 
Tetra-1: 5'GGATAGCGCGTGATCGGAACGCCTACGATGG 
ACACGCCGACC3’ 
Tetra-2: 
5'GGTCGGCGTGTGGTTGCGCTCTAGGCAGTGGTTTGACGTCCGCATGT
TGGGAATAGCCACGCCT3’ 
Tetra-3: 5'GAGCGCAACCTCCCTGGCAAGACTCCAGAGG 
ACTACTCATCC3’ 
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Tetra-4: 
5'GGATGAGTAGTGGGCTCAGTCTAGGCAGTGGTTTGACGTCCGCATGT
TGGGAATAGCCACGCCT3’ 
Tetra-5: 5'GACTGAGCCCTGCTAGGATCGACTTCACTGG 
ACCGTTCTACC3’ 
Tetra-6: 
5'GGTAGAACGGTGGAAGCCAACTAGGCAGTGGTTTGACGTCCGCATG
TTGGGAATAGCCACGCCT3’ 
Tetra-7: 5'GTTGGCTTCCTGTACGGCAGAACTCCGTTGG 
ACGAACACTTCC3’ 
Tetra-8: 
5'GGAGTGTTCGTCGCGCTATCCTAGGCAGTGGTTTGACGTCCGCATGT
TGGGAATAGCCACGCCT3’ 
Tetra-9: 
5'AGGGACCATCGTAGGTTTTCGTTCCGATCACCAACGGAGTTTTTTCTG
CCGTACACCAGTGAAGTTTTTCGATCCTAGCACCTCTGGAGTTTTTCTT
GCC3’ 
Short Tetra-4: 5'GGATGAGTAGT GGGCTCAGTC3’ 
Five-point-star tile: 
L-1:  
5'GTGTCGCGGTTTTAAGCGATTAGGCAGTGGTTTGACGTCCGCATGTT
GGGAATAGCCACGCCT3’ 
L-2: 5'ATCGCTTAAAATCTTAGTAGGCTTAGTATGGGTACTGTCGG3’ 
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L-3: 
5'CCGACAGTACATATATAAGATAGGCAGTGGTTTGACGTCCGCATGTT
GGGAATAGCCACGCCT3’ 
L-4: 5'TCTTATATATTAGGACAAGTGGCACAGTTTCATTTTAGTAT3’ 
L-5:  
5'ATACTAAAATGACGCCGAGTTAGGCAGTGGTTTGACGTCCGCATGTT
GGGAATAGCCACGCCT3’ 
L-6: 5'ACTCGGCGTCCTTGACCCTATGGGATATATGCGGCTAAATT3’ 
L-7:  
5'AATTTAGCCGCTGCGGAACTTAGGCAGTGGTTTGACGTCCGCATGTT
GGGAATAGCCACGCCT3’ 
L-8: 5'AGTTCCGCAGATCTCCGATGTCGTACACACTATTAGTT3’ 
L-9: 
5'ATTGTTGGACTCAACAAGTCCACTAGGGAAGGAGACCGCGACAC3’ 
L-10:  
5'AAGATCTCCTTCCCTTTTTTAGTGGACTTGTAGTGTGTACGTTTTTAC
ATCGGAGATCATATATCCCTTTTTATAGGGTCAAGGAAACTGTGCTTTT
TCACTTGTCCTACCATACTAAGTTTTTCCTACT3’ 
R-1: 
5'CCTGACAACCTAATGATGTTTAGCCAAGGTAACCAGTACAAGGTGCT
AAACGTAATGGCTTCGGCTTAC3’ 
R-2: 5'AACATCATTACTAGGGAAGGACGCGTTGGATGGTATCAGGT3’ 
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R-3:  
5'TACACATCCAACGCGTTTTTTCCTTCCCTAGCTCGGCCACGTTTTTCT
GTAATCTACTGGGTACTTCTTTTTGCCTAGTCAGACATTGAATTCTTTT
TGGCATTATCTCCGTGGTCTCATTTTTCGGTAT3’ 
R-4: 5'ACAGGGCAGGGTAGATTACAGCGTGGCCGAGGGTTGTCAGG3’ 
R-5: 5'AAGGGTTAGATCTGACTAGGCGAAGTACCCACCAAGAGAAA3’ 
R-6:  
5'TTTCTCTTGGCCTGCCCTGTTAGCCAAGGTAACCAGTACAAGGTGCT
AAACGTAATGGCTTCGGCTTAC3’ 
R-7: 
5' CGCTAATGGTGACGGAGATAATGCCGAATTCAATGATGCCATCGG3’ 
R-8:  
5'CCGATGGCATTCTAACCCTTTAGCCAAGGTAACCAGTACAAGGTGCT
AAACGTAATGGCTTCGGCTTAC3’ 
R-9:  
5'ACCTGATACCCAGGTATGCATAGCCAAGGTAACCAGTACAAGGTGCT
AAACGTAATGGCTTCGGCTTAC3’ 
R-10: 5'TGCATACCTGGTGTAATACCGTGAGACCACGCGTTGCTC3’ 
R-11: 5’CCAACAATGAGCAACGCGTCACCA3’ 
L/R-
11:5’TTAGCGAACTAATTGAGTCCAACAATGAGCAACGCGTCACCA3’ 
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Hetero 26-mer bi-specific aptamer 
26-1: 
5’CATGGCATGCCAGCCGGTCATGCGGACCAACCTGAGGTGAAGATTTT
CGCAACAACAGCCGACGGACT3’ 
26-2: 
5’CATGGCAGGGCTAACTTCAACTACTCCTGTTTCCCGCCGGAGGCTAT
CAATAG ATGACCGGCTGGCAT3’ 
26-3: 
5’/phos/GCCATGTAGCCAAGGTAACCAGTACAAGGTGCTAAACGTAATG
GCTTCGGCTTAC3’ 
26-4: 
5’CATGGCGCGCCGAATCGTCATCTATTGATAGCCTCCGGCGGGAAAC
AGGAGT AATCAACGTGATCCAT3’ 
26-5: 
5’CATGGCATGTCCACAATAACCGTTGCGAAAATCTTCACCTCAGGTTG
GTCCGC ATGACGATTCGGCGC3’ 
26-6: 5’CATGGCTCGACGTATCCACAC 
GTCTATCTCCGTGGGACGAGCCAACGCCTGGC GTCCTTCGCATATGC3’ 
26-7: 5’CATGGCGCATATGCGAAGGAC 
AGCCGGTGCGGGCACGAGGGCTAGCCAAGGTAACCAGTACAAGGTGC
TAAACGTAATGGCTTCGGCTTAC3’ 
26-8: 5’GCCCTCGTGCCCGCACCGGCTGGACCGCCAACAGAG3’ 
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26-9: 
5’CATGGCCTCTGTTGGCGGTCCGCCAGGCGTTGGCTCGTCCCACGGAG
ATAGAC GCCACAGACTCCCTA3’ 
26-10: 5’CATGGCTAGGGAGTCTGTGGC 
GGGCCTCATGCTCGAGACGCCTGCCCTTCTTG GTTGAAGTTAGCCCT3’ 
26-11: 
5’CATGGCATGGATCACGTTGATCAAGAAGGGCAGGCGTCTCGAGCAT
GAGGCCC GTGTGGATACGTCGA3’ 
26-12: 
5’CATGGCAGTCCGTCGGCTGTTAGGAGCACGTTCGTAATATTCCGGAA
ACTTTA TAGGTCTGCAGCAGC3’ 
26-13: 
5’CATGGCCGCTATGATTTAGTATAAAGTTTCCGGAATATTACGAACGT
GCTCCT GGTTATTGTGGACAT3’ 
26-14: 
5’CATGGCGCTGCTGCAGACCTAACTAGCGGCTACCTGGATTTGTTTCC
TATGTGCAACCTGGCA CAGCTGTCTAAACGC3’ 
26-15: 
5’CGCATATGCCCAAGTGGCGTTTGCCAGGTTGCACATAGGAAACAAA
TCCAGGTAGCCGCTAGT TACTAAATCATAGCG3’ 
26-16: 
5’CGCATAGCGTTTAGACAGCTGCTCAGTGCCGATACCGCCCGATCTGC
GCATCG CGTAGACTCCGGGGA3’ 
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26-17: 
5’CGCATATCCCCGGAGTCTACGCCTCTTCGCACTTTCCTTTTCTCCGGT
TGATC TGGATGGTTCTCACA3’ 
26-18: 
5’CGCATATGTGAGAACCATCCAGGGATCGGGCCGGGCCAAGGCATGG
GCTGGGC ACGGAGAGATATGAC3’ 
26-19: 
5’CGCATAGTCATATCTCTCCGTCGAGCCAAGAAGAGGTGGCTCCCGGC
CAGCGCAGCGTACGCAACTCT3’ 
26-20: 
5’CGCATAAGAGTTGCGTACGCTAGCCGACCGCCTCCCGCTCAGGCGTT
CGGGCC TACAGCCTAATGGCC3’ 
26-21: 
5’CGCATAGGCCATTAGGCTGTAGGCTCTGTAGCTGGGGCCAGCTAGGC
AGTGGTTTGACGTCCGCATGTTG GGAATAGCCACGCCT3’ 
26-22: 5’GCTGGCCCCAGCTACAGAGCC ACAAACGAACCTCAT3’ 
26-23: 
5’CGCATAATGAGGTTCGTTTGTGGCCCGAACGCCTGAGCGGGAGGCG
GTCGGCT TGAACGACTGCCTTG3’ 
26-24: 
5’CGCATACAAGGCAGTCGTTCAGCGCTGGCCGGGAGCCACCTCTTCTT
GGCTCG ATCCACTGCCGTAAA3’ 
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26-25: 
5’CGCATATTTACGGCAGTGGATGCCCAGCCCATGCCTTGGCCCGGCCC
GATCCC GCTAAATCTCCCGCA3’ 
26-26: 
5’CGCATATGCGGGAGATTTAGCGATCAACCGGAGAAAAGGAAAGTGC
GAAGAGG CGGGCAACGCGGGGA3’ 
26-27: 
5’CGCATATCCCCGCGTTGCCCGCGATGCGCAGATCGGGCGGTATCGGC
ACTGAG AACGCCACTTGGGCA3’ 
26-28: 
5’/phos/TATGCGTAGGCAGTGGTTTGACGTCCGCATGTTGGGAATAGCC
ACGCCT3’ 
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APPENDIX B 
SUPPLEMENTAL INFORMATION FOR CHAPTER 3 
(A DNA NANOSTRUCTURE PLATFORM FOR DIRECTED ASSEMBLY OF 
SYNTHETIC VACCINES) 
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Supplemental Figure S3.1 Structure and sequence of the tetrahedral DNA and 
branched DNA nanostructure. 
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DNA strands: All the DNA strands were purchased from Integrated DNA 
Technologies Inc. (CA), and the DNA strand sequences are listed as follows (* 
indicates phosphothioate bond): 
Strand-L: 5’ AGG CAC CAT CGT AGG TTT C TTG CCA GGC ACC ATC 
GTA GGT TTCT TGC CAG GCA CCA TCG TAG GTT T CTT GCC 3’ 
Strand-M-linker: 5’ CAG AGG CGC TGC AAG CCT ACG ATG GAC ACG 
GTA ACG ACT 3’ 
Strand-CpG-linker: 5’ AGC AAC CTG CCT GTT AGC GCC TCT GTT TTT 
T*C*C *A*T*G *A*C*G *T*T*C*C*T*G*A*C*G*T*T 3’ 
Strand-S: 5’ /5Biosg/TTA CCG TGT GGT TGC TAG TCG TT 3’ 
CpG ODN: 5’ TCC ATG ACG TTC CTG ACG TT 3’ 
Biotin-CpG:5’/5Biosg/T*C*C*A*T*G*A*C*G*T*T*C*C*T*G*A*C*G*T*T3’  
Branch-1: 5’ TAG ATA CGA GGT CCA AGG AAT TTT TT*C*C *A*T*G 
*A*C*G *T*T*C*C*T*G*A*C*G*T*T 3’ 
Branch-2: 5’ TTC CTT GGA CGA TTG CGT GC 3’ 
Branch-3: GCA CGC ATT CGC AAG ACG GC 3’ 
Branch-4 (also designated as biotin-ODN): 5’ /5Biosg/GCC GTC TTG CCT CGT 
ATC TA 3’ 
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Branch-5: 5’ TAG ATA CGA GGC CCA AGG AA 3’ 
The DNA strands (Strand-L, Strand-M-linker, Strand-CpG-linker and Strand-S) 
were mixed at a molar ratio of 1:3:3:3 (L:M:CpG:S) in a Tris–acetic acid–EDTA–
Mg2+ buffer and the mixture was slowly cooled from 95°C to 4°C over 48 hours. 
The assembled DNA structure is designated as “Tetrahedron-CpG” and 
characterized by 3.5% non-denaturing PAGE at 20°C. 
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Figure S3.2 Non-denaturing PAGE to demonstrate the assembly of Tetrahedron-
CpG- STV complexes. (a) 3.5% non-denaturing PAGE gel to compare the purity 
of the Tetrahedron-CpG structure before and after agarose gel purification; (b) 
3.5% non- denaturing PAGE showing the assembly of streptavidin on the 
tetrahedron-CpG-STV and branch-CpG-STV complexes. The gel on the left was 
stained by ethidium bromide and the gel on the right was stained by coomassie 
blue. Ladders are 100bps; (c) 3.5% non- denaturing PAGE gel to compare the 
mobility of the tetrahedron and STV-loaded tetrahedron structures. 
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Figure S3.3 Stability of the DNA scaffold in fetal bovine serum (FBS). 
Tetrahedral DNA structures were incubated with FBS at a ratio of 1:1 (v:v) at 
room temperature for 0.5, 1, 3, and 5 hours. The integrity of the DNA scaffolds 
was evaluated by non-denaturing agarose gel electrophoresis (1.2% agarose). A 
100bp DNA ladder is included in the far left lane in the gel. 
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Figure S3.4 Antigen internalization in mouse B cell line A20. The internalization 
of directly linked ODN-STV in RAW 254.7 cells after 15 minute incubation is 
also plotted here for comparison. Antigen internalization in B cells is generally 
much weaker than in RAW 264.7 cells. 
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Figure S3.5. Confocal microscopy images showing co-localization of PE 
fluorescence from STV-PE and green fluorescence from a pH sensitive lysosomal 
dye, LysoSensor, in RAW 264.7 cells after 2hr incubation. The cartoons to the 
left of each row represent STV, directly linked ODN-STV, and tetrahedron-STV, 
respectively. 
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Figure S3.6 Antibody response in BALB/C mice. (a) Anti-STV IgG level 18 days 
after antigen challenge. Single asterisk indicates a p value of less than 0.05 as 
determined by an unpaired student t test, and double asterisk indicates a p value of 
less than 0.01 as determined by an unpaired student t test; (b) Specific memory B 
cell response in mice assessed by ELISPOT, scored by the number of antibody 
secreting cells (ASC). The average was calculated from the results of at least eight 
mice per group and the asterisk indicates a p value of less than 0.05 as determined 
by an unpaired student t test. 
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Figure S3.7 In vitro antigen internalization and in vivo antibody response induced 
by a branched DNA nanostructure. a, Antigen internalization of both DNA 
nanostructures in RAW 264.7 cells after 2 hour incubation. b, Antibody response 
in mice immunized with both DNA nanostructure-STV-CpG ODN complexes 13 
days post antigen challenge. The average antibody level was calculated from the 
results of at least eight mice per group and is plotted here. The error bars are 
generated from the standard deviation. Stars indicate p values less than 0.05 
according to a one-tailed unpaired student t test. 
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Figure S3.8 Response against the tetrahedron-shaped DNA nanostructure. Results 
analyzed by ELISA. Relative OD indicates the ratio between the measured 
OD650 for each sample and that of the negative control provided by the 
manufacture of anti-dsDNA ELISA kit. For the anti-dsDNA positive control 
provided in the anti-dsDNA ELISA kit, the relative OD is about ten-fold higher 
than the relative OD in the free CpG+STV group and tetrahedron-CpG-STV 
group. 
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APPENDIX C 
SUPPLEMENTAL INFORMATION FOR CHAPTER 4 
(DEVELOPMENT OF A DNA-SCAFFOLDED NICOTINE VACCINE 
COMPLEX) 
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Supplemental figure S4.1 Strand sequence information of DNA nanostructures. a) 
12-arm junction DNA structure used for animal injection. The CpG ODN 
sequences are modified with phosphothioate bond, as indicated by asterisk 
between bases. b) 12-arm junction DNA structure without any CpG ODN used for 
internalization experiments. Strand 12-2 is labeled with AlexFluo488 at the 5’ end 
(as indicated by green sphere) and strand 12-1 is labeled with TAMRA at the 3’ 
end (as indicated by red star). c) 8-arm junction DNA structure without any CpG 
ODN used for internalization experiments. d) 4-arm junction DNA structure 
without any CpG ODN used for internalization experiments 
 
d 
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DNA sequences: 
All the DNA strands are synthesized by Integrated DNA Technologies, Inc., and 
purified by HPLC (fluorophore labeled strands) or denaturing PAGE (all the other 
strands) before conjugation reactions or structure assembly. The strands 12-2, 12-
5, 12-8, and 12-11 are labeled with amine group at the 5’ end, and used for 
conjugation to nicotine hapten; the strands 12-3, 12-6, 12-9 and 12-12 are labeled 
with amine group at the 5’ end and used for conjugation to T-helper peptide, as 
described in 4.3.? 
Strand sequences: 
12-1  
5’ T*C*C* A*T*G* A*C*G* T*T*C* C*T*G* A*C*G* T*TG GCA CAG 
CTA TAA TAA CGC AAT CCT CTC CGG CCT CAA ACT ACT TTA CC 3’ 
12-2  
5’ /5AmMC6/GGT AAA GTA GTT TGA GGC CGG AGA CCG AAT GGA 
GTC TGT TCT CGA CGC 3’ 
12-3  
5’ /5AmMC6/GCG TCG AGA ACA GAC TCC ATT CGG ACA ATT ACG 
AAC CAA CTT AGG ACC 3’ 
12-4  
5’ T*C*C* A*T*G* A*C*G* T*T*C* C*T*G* A*C*G* T*TG GTC CTA AGT 
TGG TTC GTA ATT GTG GTC ATC GTG GCG TAC CAT ATA CC 3’ 
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12-5  
5’ /5AmMC6/GGT ATA TGG TAC GCC ACG ATG ACC TCT TCG ATC TAC 
CCG ATA GGC TCC 3’ 
12-6  
5’ /5AmMC6/GGA GCC TAT CGG GTA GAT CGA AGA CGT ACA GGT 
GTG ACT TGA ATT TGC 3’ 
12-7  
5’ T*C*C* A*T*G* A*C*G* T*T*C* C*T*G* A*C*G* T*TG CAA ATT 
CAA GTC ACA CCT GTA CGA GTG TTA GAA TAC AAC AAG CGA CC 3’ 
12-8  
5’ /5AmMC6/GGT CGC TTG TTG TAT TCT AAC ACT GCA TCT CAT ACG 
GCA GTA TCC GCC 3’ 
12-9  
5’ /5AmMC6/GGC GGA TAC TGC CGT ATG AGA TGC TGA GCA CGG 
AAC TGT CAA CCT TGC 3’ 
12-10  
5’ T*C*C* A*T*G* A*C*G* T*T*C* C*T*G* A*C*G* T*TG CAA GGT 
TGA CAG TTC CGT GCT CAC GTT CAT TAA GAT AAA TCT GAT CC 3’ 
12-11 
5’ /5AmMC6/GGA TCA GAT TTA TCT TAA TGA ACG ACT ATG CCT GCT 
ACA TGC ACT TCC 3’ 
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12-12  
5’ /5AmMC6/GGA AGT GCA TGT AGC AGG CAT AGT GGA TTG CGT 
TAT TAT AGC TGT GCC 3’ 
12-1 no CpG 
5’ G GCA CAG CTA TAA TAA CGC AAT CCT CTC CGG CCT CAA ACT 
ACT TTA CC 3’ 
12-4 no CpG 
5’ G GTC CTA AGT TGG TTC GTA ATT GTG GTC ATC GTG GCG TAC 
CAT ATA CC 3’ 
12-7 no CpG 
5’ G CAA ATT CAA GTC ACA CCT GTA CGA GTG TTA GAA TAC AAC 
AAG CGA CC 3’ 
12-10 no CpG 
5’ G CAA GGT TGA CAG TTC CGT GCT CAC GTT CAT TAA GAT AAA 
TCT GAT CC 3’ 
AF488-12-2  
5’ G GCA CAG CTA TAA TAA CGC AAT CCT CTC CGG CCT CAA ACT 
ACT TTA CCA 3’ 
TAMRA-12-1 
5’ TGGT AAA GTA GTT TGA GGC CGG AGA CCG AAT GGA GTC TGT 
TCT CGA CGC 3’ 
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Supplemental figure S4.2 Dynamic light scattering (DLS) measurement of the 
total vaccine complex sizes. The measured raidus of fully assembled 12-arm 
vaccine complex is 7.185±0.520 nm. (DLS measurement is done by Xixi Wei in 
Dr. Yan Liu’s group at Department of Chemistry and Biochemistry, Arizona State 
University. 
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